<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) - Martínez, G - 2017 | Cochrane Library</title> <meta content="18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) - Martínez, G - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012884/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) - Martínez, G - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012884/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012884" name="dc.identifier" scheme="DOI"/> <meta content="18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)" name="citation_title"/> <meta content="Gabriel Martínez" name="citation_author"/> <meta content="gmartinez@cochrane.es" name="citation_author_email"/> <meta content="Robin WM Vernooij" name="citation_author"/> <meta content="Iberoamerican Cochrane Centre" name="citation_author_institution"/> <meta content="Paulina Fuentes Padilla" name="citation_author"/> <meta content="Javier Zamora" name="citation_author"/> <meta content="Ramon y Cajal Institute for Health Research (IRYCIS), CIBER Epidemiology and Public Health (CIBERESP), Madrid (Spain) and Women's Health Research Unit, Centre for Primary Care and Public Health, Queen Mary University of London" name="citation_author_institution"/> <meta content="Leon Flicker" name="citation_author"/> <meta content="University of Western Australia" name="citation_author_institution"/> <meta content="Xavier Bonfill Cosp" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD012884" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/11/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012884/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012884/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012884/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Positron‐Emission Tomography; Alzheimer Disease [*diagnostic imaging, metabolism]; Amyloid; Aniline Compounds [economics, *pharmacokinetics]; Benzothiazoles [economics, *pharmacokinetics]; Biomarkers; Cognitive Dysfunction [complications, *diagnostic imaging, metabolism]; Confidence Intervals; Disease Progression; Early Diagnosis; False Negative Reactions; False Positive Reactions; Follow‐Up Studies; Radiopharmaceuticals [economics, *pharmacokinetics]; Reference Standards; Sensitivity and Specificity; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012884&amp;doi=10.1002/14651858.CD012884&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012884\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012884\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012884\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012884\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012884",title:"18F PET with flutemetamol for the early diagnosis of Alzheimer\u0027s disease dementia and other dementias in people with mild cognitive impairment (MCI)",firstPublishedDate:"Nov 22, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012884&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012884';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012884/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012884/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012884%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012884/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012884/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012884/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012884/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012884" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012884/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012884" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012884/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012884/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3271 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012884" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-sec-0057"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-sec-0029"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-sec-0053"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012884/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/appendices#CD012884-sec-0062"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/table_n/CD012884StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/table_n/CD012884StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012884/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012884/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012884/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012884/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012884/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012884/information#CD012884-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Gabriel Martínez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012884/information#CD012884-cr-0003">Robin WM Vernooij</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012884/information#CD012884-cr-0004">Paulina Fuentes Padilla</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012884/information#CD012884-cr-0005">Javier Zamora</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012884/information#CD012884-cr-0006">Leon Flicker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012884/information#CD012884-cr-0007">Xavier Bonfill Cosp</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012884/information/en#CD012884-sec-0070">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 November 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012884/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012884">https://doi.org/10.1002/14651858.CD012884</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012884-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012884-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012884-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012884-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012884-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012884-abs-0001" lang="en"> <section id="CD012884-sec-0001"> <h3 class="title" id="CD012884-sec-0001">Background</h3> <p><sup>18</sup>F‐flutemetamol uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA‐AA) revised the diagnostic criteria for Alzheimer's disease and the confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like <sup>18</sup>F‐flutemetamol. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of <sup>18</sup>F‐flutemetamol to predict the progression from MCI to Alzheimer’s disease dementia (ADD) or other dementias has not yet been systematically evaluated. </p> </section> <section id="CD012884-sec-0002"> <h3 class="title" id="CD012884-sec-0002">Objectives</h3> <p>To determine the DTA of the <sup>18</sup>F‐flutemetamol PET scan for detecting people with MCI at time of performing the test who will clinically progress to ADD, other forms of dementia (non‐ADD) or any form of dementia at follow‐up. </p> </section> <section id="CD012884-sec-0003"> <h3 class="title" id="CD012884-sec-0003">Search methods</h3> <p>The most recent search for this review was performed in May 2017. We searched MEDLINE (OvidSP), Embase (OvidSP), PsycINFO (OvidSP), BIOSIS Citation Index (Thomson Reuters Web of Science), Web of Science Core Collection, including the Science Citation Index (Thomson Reuters Web of Science) and the Conference Proceedings Citation Index (Thomson Reuters Web of Science), LILACS (BIREME), CINAHL (EBSCOhost), ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">https://clinicaltrials.gov</a>), and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">http://www.who.int/ictrp/search/en/</a>). We also searched ALOIS, the Cochrane Dementia &amp; Cognitive Improvement Group’s specialised register of dementia studies (<a href="http://www.medicine.ox.ac.uk/alois/" target="_blank">http://www.medicine.ox.ac.uk/alois/</a>). We checked the reference lists of any relevant studies and systematic reviews, and performed citation tracking using the Science Citation Index to identify any additional relevant studies. No language or date restrictions were applied to the electronic searches. </p> </section> <section id="CD012884-sec-0004"> <h3 class="title" id="CD012884-sec-0004">Selection criteria</h3> <p>We included studies that had prospectively defined cohorts with any accepted definition of MCI at time of performing the test and the use of <sup>18</sup>F‐flutemetamol scan to evaluate the DTA of the progression from MCI to ADD or other forms of dementia. In addition, we only selected studies that applied a reference standard for Alzheimer’s dementia diagnosis, for example, National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS‐ADRDA) or Diagnostic and Statistical Manual of Mental Disorders‐IV (DSM‐IV) criteria. </p> </section> <section id="CD012884-sec-0005"> <h3 class="title" id="CD012884-sec-0005">Data collection and analysis</h3> <p>We screened all titles and abstracts identified in electronic‐database searches. Two review authors independently selected studies for inclusion and extracted data to create two‐by‐two tables, showing the binary test results cross‐classified with the binary reference standard. We used these data to calculate sensitivities, specificities, and their 95% confidence intervals. Two independent assessors performed quality assessment using the QUADAS‐2 tool plus some additional items to assess the methodological quality of the included studies. </p> </section> <section id="CD012884-sec-0006"> <h3 class="title" id="CD012884-sec-0006">Main results</h3> <p>Progression from MCI to ADD was evaluated in 243 participants from two studies. The studies reported data on 19 participants with two years of follow‐up and on 224 participants with three years of follow‐up. Nine (47.4%) participants converted at two years follow‐up and 81 (36.2%) converted at three years of follow‐up. </p> <p>There were concerns about participant selection and sampling in both studies. The index test domain in one study was considered unclear and in the second study it was considered at low risk of bias. For the reference standard domain, one study was considered at low risk and the second study was considered to have an unclear risk of bias. Regarding the domains of flow and timing, both studies were considered at high risk of bias. </p> <p>MCI to ADD;</p> <p>Progression from MCI to ADD at two years of follow‐up had a sensitivity of 89% (95% CI 52 to 100) and a specificity of 80% (95% CI 44 to 97) by quantitative assessment by SUVR (n = 19, 1 study). </p> <p>Progression from MCI to ADD at three years of follow‐up had a sensitivity of 64% (95% CI 53 to 75) and a specificity of 69% (95% CI 60 to 76) by visual assessment (n = 224, 1 study). </p> <p>There was no information regarding the other two objectives in this systematic review (SR): progression from MCI to other forms of dementia and progression to any form of dementia at follow‐up. </p> </section> <section id="CD012884-sec-0007"> <h3 class="title" id="CD012884-sec-0007">Authors' conclusions</h3> <p>Due to the varying sensitivity and specificity for predicting the progression from MCI to ADD and the limited data available, we cannot recommend routine use of <sup>18</sup>F‐flutemetamol in clinical practice. <sup>18</sup>F‐flutemetamol has high financial costs; therefore, clearly demonstrating its DTA and standardising the process of the <sup>18</sup>F‐flutemetamol modality is important prior to its wider use. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012884-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012884-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012884-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012884-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012884-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012884-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012884-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012884-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012884-abs-0003" lang="en"> <h3>18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment </h3> <p><b>Review question:</b> In people with mild cognitive impairment (MCI), does using a <sup>18</sup>F PET scan with flutemetamol predict the progression to Alzheimer's disease dementia (ADD) and other dementias? </p> <p><b>Background</b> <br/> Due to global ageing, the number of people with dementia is expected to increase dramatically in the next few decades. Diagnosing dementia at an early stage is desirable, but there is no widespread agreement on the best approach. A range of simple pen and paper tests used by healthcare professionals can assess people with poor memory or cognitive impairment. Whether or not using special PET scans that detect amyloid —one of the hallmarks of Alzheimer's disease— improves our ability to predict the progression from MCI to ADD or other forms of dementia remains unclear. Since these tests are expensive, it is important that they provide additional benefits. </p> <p><b>Aim</b> </p> <p>We aimed to evaluate the accuracy of the <sup>18</sup>F‐flutemetamol PET scan in identifying those people with MCI who clinically progress to ADD, other types of dementia, or any form of dementia over a period of time. </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to May 2017. We found two studies evaluating the progression from MCI to ADD. The studies included 252 MCI eligible participants, with 243 participants that had follow‐up. Of these, 127 were women. The average age in one study with two years of follow‐up was 72.7 + 7.09 years. In the other study with three years of follow‐up, the average age was 71.1 + 8.62 years. The setting in one study was memory clinics. </p> <p>Study funding sources: both studies were funded by the test manufacturer.</p> <p><b>Quality of the evidence</b> </p> <p>The main limitation of this review was that our findings were based on only two studies, with not enough details on how the people were selected, how the interpretation of the PET scan was made in one study, how the clinical diagnosis of dementia was established in the other study. The studies were considered to be at high risk of bias due to potential conflicts of interest detected. </p> <p><b>Key findings</b> </p> <p>In this review, we found that the <sup>18</sup>F‐flutemetamol PET scan, as a single test, in one study with 19 participants included with 2 years of follow‐up, had a sensitivity of 89% and a specificity of 80%. This means that in a cohort with 100 participants with MCI and a proportion of progression in this study of 47%, we would expect 42 of 47 MCI participants with a positive result for <sup>18</sup>F‐flutemetamol scan to progress to ADD, and 5 participants to be falsely positive. In addition, we would expect 42 of 53 participants who will not progress to ADD to have a negative result for <sup>18</sup>F‐flutemetamol, and 11 to be falsely negative. </p> <p>In the other study with 224 participants included in the analysis with 3 years follow‐up, the sensitivity was 64% and the specificity was 69%. This means that in a cohort with 100 participants with MCI and a proportion of progression in this study of 36%, we would expect 23 of 36 MCI participants with a positive result for <sup>18</sup>F‐flutemetamol to progress to ADD, and 13 participants to be falsely positive. In addition, we would expect 44 of 64 participants who will not progress to ADD to have a negative result for <sup>18</sup>F‐flutemetamol, and 20 to be falsely negative. </p> <p>There was no information regarding the progression from MCI to other forms of dementia and progression to any form of dementia at follow‐up. </p> <p>We conclude that <sup>18</sup>F‐flutemetamol PET imaging cannot be recommended for routine use in clinical practice to predict the progression from MCI to ADD based on the currently available data. More studies are needed to clearly demonstrate its usefulness. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012884-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012884-sec-0057"></div> <h3 class="title" id="CD012884-sec-0058">Implications for practice</h3> <section id="CD012884-sec-0058"> <p>As of today, the use of <sup>18</sup>F‐flutemetamol has not been established for predicting development of Alzheimer's disease (<a href="./references#CD012884-bbs2-0039" title="Food , DrugAdministration . Vizamyl. www.accessdata.fda.gov/drugsatfda_docs/label/2014/203137s002lbl.pdf (accessed 8 April 2015). ">FDA 2014</a>; <a href="./references#CD012884-bbs2-0036" title="European Medicines Agency. Vizamyl. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002557/WC500172950.pdf (accessed 8 April 2015). ">EMA 2014</a>), and is not indicated in people with MCI, except in clinical trials and research studies ( <a href="./references#CD012884-bbs2-0014" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2011;7(3):270‐9. ">Albert 2011</a>). </p> <p>However, the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association have proposed the usage of amyloid PET in people with persistent or progressive unexplained MCI (<a href="./references#CD012884-bbs2-0055" title="JohnsonKA , MinoshimaS , BohnenNI , DonohoeKJ , FosterNL , HerscovitchP , et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Journal of nuclear medicine : official publication, Society of Nuclear Medicine2013;54(3):476‐90. ">Johnson 2013</a>). The DTA of <sup>18</sup>F‐flutemetamol PET scans, as determined in this SR, has a variable sensitivity and specificity based on two studies with 243 participants at follow‐up to predict the progression from MCI to ADD. </p> <p>Due to the aforementioned and the methodological limitations of the included studies, it is not possible to recommend the routine use of <sup>18</sup>F‐flutemetamol in clinical practice. The <sup>18</sup>F‐flutemetamol biomarker is expensive, therefore it is important to clearly determine its DTA and to standardise the process for the diagnostic modality prior to it being recommended for clinical practice. </p> </section> <h3 class="title" id="CD012884-sec-0059">Implications for research</h3> <section id="CD012884-sec-0059"> <p>FDA and EMA have established the <sup>18</sup>F‐flutemetamol criteria positivity in order to use these in ADD patient evaluation and their use in MCI participants is accepted in research settings and clinical trials (<a href="./references#CD012884-bbs2-0014" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2011;7(3):270‐9. ">Albert 2011</a>). However, their use has also been proposed in clinical practice to evaluate people with MCI by the Nuclear Medicine Society and the Alzheimer's Association (<a href="./references#CD012884-bbs2-0055" title="JohnsonKA , MinoshimaS , BohnenNI , DonohoeKJ , FosterNL , HerscovitchP , et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Journal of nuclear medicine : official publication, Society of Nuclear Medicine2013;54(3):476‐90. ">Johnson 2013</a>). It is still used in many studies with different <sup>18</sup>F‐flutemetamol SUVRs, visual assessment, or both. This promotes different accuracies for the tracer even in people with ADD when are compared with HC. Therefore, it is necessary to consider visual assessment as the most important option to interpret the <sup>18</sup>F‐flutemetamol PET scan, because this is the approach to the interpretation established by FDA and EMA (<a href="https://archie.cochrane.org/sections/documents/view?version=z1710170141070814151480284612955%26format=REVMAN#REF-EMA-2014" target="_blank">EMA 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1710170141070814151480284612955%26format=REVMAN#REF-FDA-2014" target="_blank">FDA 2014</a>). </p> <p>On the other hand, clinical assessment in people with memory complaints is not always made with only one test; one could add different tests such as volumetric hyppocampal MRI, FDG‐PET, SPECT, CSF, and others. This suggestion has face validity because neurodegenerative diseases are complex disorders with occasionally multiple and overlapping pathophysiological processes. Multitracer imaging may be helpful in combining metabolic, inflammation, or apoptosis markers with those labelling typical protein aggregations seen in the progression of MCI to Alzheimer’s disease. In future, various PET imaging modalities are needed to evaluate the usefulness of the various PET tracers as predictors of progression to Alzheimer’s disease in MCI studies with clinical follow‐up. There is a hypothesis that amyloid deposition is an early event in Alzheimer’s disease that reaches a relative plateau even at the MCI stage, while downstream biomarkers measure neuronal loss and dysfunction, and cognitive measures are more dynamic at the symptomatic disease stage (<a href="./references#CD012884-bbs2-0053" title="JackCRJr , KnopmanDS , JagustWJ , ShawLM , AisenPS , WeinerMW . Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurology2010;9(1):119‐28. ">Jack 2010</a>). Based on this hypothesis, the combination of structural imaging, functional imaging, and cognitive tests may be better predictors of when an individual will convert. However, there is a lack of studies with <sup>18</sup>F‐flutemetamol combined with other tests to predict the progression from MCI to ADD or any form of dementia. </p> <p>Additionally, if we consider the hierarchical evidence needed for level of efficacy of diagnostic imaging tests, we are currently in the second step of six according to Herscovitch (<a href="./references#CD012884-bbs2-0049" title="HerscovitchP . Regulatory approval and insurance reimbursement: the final steps in clinical translation of amyloid brain imaging. Clinical and translational imaging2015;3:75‐7. ">Herscovitch 2015</a>): technical efficacy, diagnostic accuracy efficacy, diagnostic thinking efficacy, therapeutic impact, patient health outcomes, and finally societal efficacy. Therefore, we need further research about accuracy before progressing to the other steps with their specific studies before we can incorporate the <sup>18</sup>F‐flutemetamol PET scan into clinical practice. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012884-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012884-sec-0022"></div> <div class="table" id="CD012884-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">DTA of 18F‐flutemetamol to predict the progression to ADD in people with MCI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>What is the diagnostic accuracy of <sup>18</sup>F‐flutemetamol PET amyloid biomarker for predict progression to ADD in people with MCI? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>Descriptive</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Patient population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Participants diagnosed with MCI at the time of performing the test using any of the Petersen criteria or Winblad criteria or CDR = 0.5 or any of the 16 definitions included by Matthews (<a href="./references#CD012884-bbs2-0064" title="MatthewsFE , StephanBC , McKeithIG , BondJ , BrayneC , Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008;56(8):1424‐33. ">Matthews 2008</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Sources of referral</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Not reported (n = 2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>MCI criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Petersen criteria (n = 2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Sampling procedure</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Unclear (n = 2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Prior testing</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>The only testing prior to performing the <sup>18</sup>F‐flutemetamol PET amyloid biomarker was the application of diagnostic criteria for identifying participants with MCI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Settings</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Secondary care (n = 1)</p> <p>Not reported (n = 1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Index test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><sup>18</sup>F‐flutemetamol PET </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Threshold pre‐specified at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Yes (n=1)</p> <p>Unclear (n=1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Threshold interpretation</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Visual (n = 1)</p> <p>Quantitative (n = 1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Thershold</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>SUVR (Standardised Uptake Volume ratio) of ROI: &gt; 1.5 (n = 1)</p> <p>Not specified: analytical visual approach of ROI: (n = 1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><sup>18</sup>F‐flutemetamol retention region </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Global cortex (n = 1)</p> <p>Not reported (n = 1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Reference Standard</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>For Alzheimer’s disease dementia:</p> <p>NINCDS‐ADRDA (n = 1)</p> <p>Unclear (n = 1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Target condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Progression from MCI to Alzheimer’s disease dementia or any other forms of dementia (non‐ADD) or any form of dementia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Included studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Prospectively well‐defined cohorts with any accepted definition of MCI (as above). Two studies (N = 252 participants) were included. Number of participants included in analysis: 243 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Quality concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a>: </p> <p>Patient selection and index test QUADAS‐2 domain: unclear risk of bias</p> <p>Reference standard domain: low risk of bias</p> <p>Flow and timing domain: high risk of bias</p> <p>There were unclear concerns about applicability in the patient selection and index test domain.<br/> <a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a>: </p> <p>Patient selection and index test QUADAS‐2 domain: low risk of bias</p> <p>Reference standard domain: unclear risk of bias</p> <p>Flow and timing domain: high risk of bias.</p> <p>There was unclear concern about applicability in the reference standard domain.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Limitations</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Limited investigation of heterogeneity and sensitivity analysis due to an insufficient number of studies. </p> <p>We were unable to evaluate progression from MCI to any other form of dementia (non‐ADD) or any form of dementia due to lack of included studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Cases/Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Sensitivity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Specificity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Consequences in a cohort of 100</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion converting<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missed cases<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overdiagnosed</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Alzheimer's disease dementia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐flutemetamol with visual assessment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81/224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64% (95% CI 53% to 75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69% (95% CI 60% to 76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐flutemetamol with SUVR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89% (95% CI 52% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80% (95% CI 44% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Investigation of heterogeneity and sensitivity analysis</b>: The planned investigations were not possible due to the limited number of studies available for each analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Conclusions:</b><sup>18</sup>F‐flutemetamol PET scan is not an accurate test for detecting progression from MCI to Alzheimer’s disease dementia. The strength of the evidence was weak because of considerable variation in study methods, unclear methodological quality due to poor reporting, and high risk of bias due to possible conflict of interest. There is a need for conducting studies using standardised <sup>18</sup>F‐flutemetamol PET scan methodology in larger populations. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1. Proportion converting to ADD in each included study</sup> </p> <p><sup>2. Missed and overdiagnosed numbers were computed using the proportion converting to the target condition.</sup> </p> <p><sup>ADD: Alzheimer's disease dementia<br/> CDR: Clinical Dementia Rating<br/> MCI: Mild cognitive impairment<br/> NINCDS‐ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association<br/> PET: Positron emission tomography</sup> </p> <p><sup>QUADAS‐2: Quality Assessment of Diagnostic Accuracy Studies‐2<br/> ROI: Region of interest<br/> SUVR: Standardised uptake value ratio</sup> </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012884-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012884-sec-0023"></div> <p>Dementia is a syndrome due to a brain disease — usually of a chronic or progressive nature — in which there is disturbance of multiple higher cortical functions, including memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement. However, consciousness remains unaffected. See the glossary in <a href="./appendices#CD012884-sec-0063">Appendix 1</a>. The impairments of cognitive function are commonly accompanied, and occasionally preceded, by a deterioration in emotional control, social behaviour, motivation, and the impairment is sufficient to interfere with everyday activities. Dementia is a collection of different subtypes distinguished by the underlying pathology. ADD is the most common form of dementia and other important pathologies associated with dementia are vascular disease, Lewy bodies, and frontotemporal pathology (<a href="./references#CD012884-bbs2-0105" title="World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. 2012. http://www.who.int/mental_health/publications/dementia_report_2012/en/. World Health Organization, (accessed 23th September 2015). ">WHO 2012</a>). </p> <p>Dementia is a serious worldwide public health problem, with a prevalence of 4.7% in adults older than 60 years (6.2% and 6.5% in Europe and the Americas, respectively). Due to its prevalence in older people, it is expected that the number of people with dementia will increase dramatically. Consequently, in the year 2050, an expected number of 115 million people will have dementia. This will result in a considerable economic burden, which currently stands at 1% of the world's Gross National Product (GNP) in direct and indirect costs (<a href="./references#CD012884-bbs2-0105" title="World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. 2012. http://www.who.int/mental_health/publications/dementia_report_2012/en/. World Health Organization, (accessed 23th September 2015). ">WHO 2012</a>). These financial costs are in addition to the devastating personal and social consequences of the condition. </p> <p>The definition of MCI applies to people without evidence of significant deterioration in activities of daily living, but with subjective memory complaints and cognitive impairment detected by standardised tests. MCI often precedes clinical dementia, but there is no consensus regarding how to operationalise the MCI diagnosis. There are several clinical criteria to define which people have MCI, including the Petersen criteria or Petersen Revisited Criteria (<a href="./references#CD012884-bbs2-0080" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999;56(3):303‐8. ">Petersen 1999</a>; <a href="./references#CD012884-bbs2-0081" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004;256(3):183‐94. ">Petersen 2004</a>; <a href="./references#CD012884-bbs2-0106" title="WinbladB , PalmerK , KivipeltoM , JelicV , FratiglioniL , WahlundLO , et al. Mild cognitive impairment‐‐beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine2004;256(3):240‐6. ">Winblad 2004</a>), Clinical Dementia Rating Scale (CDR= 0.5) (<a href="./references#CD012884-bbs2-0072" title="MorrisJC . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology1993;43(11):2412‐4. ">Morris 1993</a>), or 16 other different classifications of MCI (<a href="./references#CD012884-bbs2-0064" title="MatthewsFE , StephanBC , McKeithIG , BondJ , BrayneC , Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008;56(8):1424‐33. ">Matthews 2008</a>). </p> <p>A diagnosis of MCI reputedly allows testing of preventive interventions that would slow the progression of MCI to dementia. If the progression of MCI to dementia could be deferred by five years, the prevalence of dementia would decrease by 43% in 2050 (<a href="./references#CD012884-bbs2-0015" title="Alzheimer's Association. Changing the Trajectory of Alzheimer's Disease: A National Imperative. Alzheimer's Association2010. ">Alzheimer's Association 2010</a>). MCI has an annual progression rate to ADD from 5% to 15%. However, not every person with MCI develops dementia, and a significant number of people recover or stabilise. Therefore, future research should try to clarify which people with MCI develop dementia in order to be able to focus specifically on people who are at high risk of developing dementia. This may possibly explain the failure of therapy to alter the progression to dementia in people with MCI. Other aspects that may contribute to this failure are the disparity in diagnostic criteria and different settings of the studied participants: community, primary, secondary, and research centres (<a href="./references#CD012884-bbs2-0023" title="BruscoliM , LovestoneS . Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics/IPA2004;16(2):129‐40. ">Bruscoli 2004</a>; <a href="./references#CD012884-bbs2-0065" title="MattssonN , ZetterbergH , HanssonO , AndreasenN , ParnettiL , JonssonM , et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA2009;302(4):385‐93. ">Mattsson 2009</a>; <a href="./references#CD012884-bbs2-0080" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999;56(3):303‐8. ">Petersen 1999</a>; <a href="./references#CD012884-bbs2-0082" title="PetersenRC , RobertsRO , KnopmanDS , BoeveBF , GedaYE , IvnikRJ , et al. Mild cognitive impairment: ten years later. Archives of Neurology2009;66(12):1447‐55. ">Petersen 2009</a>). </p> <p>The definition of Alzheimer's disease pathology is over 100 years old. This pathology includes neuritic plaques that contain deposits of amyloid beta (Aβ) and neurofibrillary tangles (<a href="./references#CD012884-bbs2-0044" title="GoedertM , SpillantiniMG . A century of Alzheimer's disease. Science2006;314(5800):777‐81. ">Goedert 2006</a>). This pathology is present in approximately 84% of all people with dementia (<a href="./references#CD012884-bbs2-0092" title="SchneiderJA , ArvanitakisZ , BangW , BennettDA . Mixed brain pathologies account for most dementia cases in community‐dwelling older persons. Neurology2007;69(24):2197‐204. ">Schneider 2007</a>). Furthermore, Alzheimer's disease pathology is found in 88% of people diagnosed with probable ADD (<a href="./references#CD012884-bbs2-0093" title="SchneiderJA , ArvanitakisZ , LeurgansSE , BennettDA . The neuropathology of probable Alzheimer disease and mild cognitive impairment. Annals of neurology2009;66(2):200‐8. ">Schneider 2009</a>). Despite this, Alzheimer's disease pathology may be found concomitantly at autopsy in people thought to have other forms of dementia, such as vascular dementia, Lewy body dementia, or frontotemporal dementia (FTD) (<a href="./references#CD012884-bbs2-0054" title="JellingerK . Clinicopathological analysis of dementia disorders in the elderly‐‐an update. Journal of Alzheimer's Disease: JAD2006;9(Supplement 3):61‐70. ">Jellinger 2006</a>). Furthermore, at least five common pathologies have been found in the brains of people who died and were thought to have ADD prior to death (<a href="./references#CD012884-bbs2-0103" title="WhiteL . Brain lesions at autopsy in older Japanese‐American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu‐Asia aging study. Journal of Alzheimer's Disease: JAD2009;18(3):713‐25. ">White 2009</a>). Also, Alzheimer's disease pathology was found in 42% of community‐dwelling older people without dementia (<a href="./references#CD012884-bbs2-0092" title="SchneiderJA , ArvanitakisZ , BangW , BennettDA . Mixed brain pathologies account for most dementia cases in community‐dwelling older persons. Neurology2007;69(24):2197‐204. ">Schneider 2007</a>). This has generated controversy about the importance of the presence of Alzheimer's disease pathology. The pathology can be associated with aging per se, and, for older people, the relationship between amyloid plaque burden and cognitive impairment diminishes as age progresses (<a href="./references#CD012884-bbs2-0091" title="SavvaGM , WhartonSB , IncePG , ForsterG , MatthewsFE , BrayneC , Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. The New England Journal of Medicine2009;360(22):2302‐9. ">Savva 2009</a>). Thus, this pathology could be an epiphenomenon associated with the presence of dementia, e.g. a by‐product of repair mechanisms by vascular damage (<a href="./references#CD012884-bbs2-0031" title="de laTorreJC . Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. The Lancet. Neurology2004;3(3):184‐90. ">De la Torre 2004</a>; <a href="./references#CD012884-bbs2-0041" title="Garcia‐AllozaM , GregoryJ , KuchibhotlaKV , FineS , WeiY , AyataC , et al. Cerebrovascular lesions induce transient β‐amyloid deposition. Brain: a Journal of Neurology2011;134(12):3697‐707. ">Garcia‐Alloza 2011</a>). On the other hand, this controversy could be because our clinical diagnostic criteria have not had enough accuracy to diagnose Alzheimer's disease that is detected by histopathology in postmortem studies (<a href="./references#CD012884-bbs2-0051" title="HymanBT , PhelpsCH , BeachTG , BigioEH , CairnsNJ , CarrilloMC , et al. National Institute on Aging‐Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association2012;8(1):1‐13. ">Hyman 2012</a>). In addition, other researchers think that there is not a real controversy about the amyloid hypothesis, because the amyloid cascade and the Aβ deposition have a primary role in Alzheimer's disease (<a href="./references#CD012884-bbs2-0095" title="SelkoeDJ , HardyJ . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO molecular medicine2016;8(6):595‐608. ">Selkoe 2016</a>). </p> <p>More recently, the development of Aβ pathology biomarkers in vivo has been suggested as an important advance as a diagnostic tool in the field of Alzheimer's disease, and has promoted the creation of new diagnostic criteria for people without symptoms (preclinical stages), people with MCI, and people with ADD, based on the presence of biomarkers of Alzheimer's disease. These have included Aβ tracers by positron emission tomography (PET) (<a href="./references#CD012884-bbs2-0014" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2011;7(3):270‐9. ">Albert 2011</a>; <a href="./references#CD012884-bbs2-0032" title="DuboisB , FeldmanHH , JacovaC , HampelH , MolinuevoJL , BlennowK , et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG‐2 criteria. The Lancet. Neurology2014;13(6):614‐29. ">Dubois 2014</a>; <a href="./references#CD012884-bbs2-0070" title="McKhannGM , KnopmanDS , ChertkowH , HymanBT , JackCRJr , KawasCH , et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2011;7(3):263‐9. ">McKhann 2011</a>; <a href="./references#CD012884-bbs2-0098" title="SperlingRA , AisenPS , BeckettLA , BennettDA , CraftS , FaganAM , et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2011;7(3):280‐92. ">Sperling 2011</a>). However, uncertainties regarding the usability of biomarkers in the diagnosis of dementia still exist, mainly due to variation between biomarker types, criteria for positivity, and differences in methodology (<a href="./references#CD012884-bbs2-0077" title="Noel‐StorrAH , FlickerL , RitchieCW , NguyenGH , GuptaT , WoodP , et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2013;9(3):e96‐105. ">Noel‐Storr 2013</a>). This prompted an important initiative, the Standards for Reporting of Diagnostic Accuracy Studies in dementia studies (STARDdem) statement (<a href="./references#CD012884-bbs2-0078" title="Noel‐StorrAH , McCleeryJM , RichardE , RitchieCW , FlickerL , CullumSJ , et al. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology2014;83(4):364‐73. ">Noel‐Storr 2014</a>). Consequently, clinical properties of dementia biomarkers should not be assumed, and formal systematic evaluations of sensitivity, specificity, and other properties of biomarkers should be performed (<a href="./references#CD012884-bbs2-0029" title="DavisDHJ , CreavinST , Noel‐StorrA , QuinnTJ , SmailagicN , HydeC , et al. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010460] ">Davis 2013</a>). </p> <p>PET is an imaging technique using compounds labelled with short‐lived positron‐emitting radionuclides. The use of Aβ ligands permits the in vivo detection of amyloid deposition in the brain. <sup>18</sup>F PET ligands, such as <sup>18</sup>F‐flutemetamol, is a fluorinated tracer, derived from the Pittsburgh Compound B (the first tracer developed), and it is characterised by a higher median life of 110 minutes than the Pittsburgh Compound B and a high affinity for amyloid β. The performance of the <sup>18</sup>F‐flutemetamol PET scan was probed in vivo with healthy people and ADD (<a href="./references#CD012884-bbs2-0075" title="NelissenN , VanLaereK , ThurfjellL , OweniusR , VandenbulckeM , KooleM , et al. Phase 1 study of the Pittsburgh compound B derivative 18F‐flutemetamol in healthy volunteers and patients with probable Alzheimer disease. Journal of Nuclear Medicine2009;50(8):1251‐9. ">Nelissen 2009</a>) and also in people with MCI (<a href="./references#CD012884-bbs2-0100" title="VandenbergheR , VanLaereK , IvanoiuA , SalmonE , BastinC , TriauE , et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology2010;68(3):319‐29. ">Vandenberghe 2010</a>) and it has been considered that it could eventually be used to differentiate between different dementia types, specifically between FTD and ADD like other fluorinated tracers such as <sup>18</sup>F‐florbetaben (<a href="./references#CD012884-bbs2-0101" title="VillemagneVL , OngK , MulliganRS , HollG , PejoskaS , JonesG , et al. Amyloid imaging with (18)F‐florbetaben in Alzheimer disease and other dementias. Journal of Nuclear Medicine2011;52(8):1210‐7. ">Villemagne 2011</a>) or <sup>18</sup>F‐florbetapir (<a href="./references#CD012884-bbs2-0057" title="KobyleckiC , LangheinrichT , HinzR , VardyER , BrownG , MartinoME , et al. 18F‐Florbetapir PET in patients with frontotemporal dementia and Alzheimer disease. Journal of Nuclear Medicine2015;56(3):386‐91. ">Kobylecki 2015</a>). </p> <p>In 2013, <sup>18</sup>F‐flutemetamol was approved by the Food and Drug Administration (FDA) and, in 2014, by the European Medicines Agency (EMA). A positive scan indicates moderate to frequent presence of neuritic amyloid plaques. However, this might also occur in people with other neurological conditions and in older adults with normal cognition. Therefore, the safety and effectiveness of <sup>18</sup>F‐flutemetamol have not been established for predicting development of dementia or other neurological conditions and it should be combined with other diagnostic evaluations or instruments (<a href="./references#CD012884-bbs2-0036" title="European Medicines Agency. Vizamyl. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002557/WC500172950.pdf (accessed 8 April 2015). ">EMA 2014</a>; <a href="./references#CD012884-bbs2-0039" title="Food , DrugAdministration . Vizamyl. www.accessdata.fda.gov/drugsatfda_docs/label/2014/203137s002lbl.pdf (accessed 8 April 2015). ">FDA 2014</a>). </p> <p>Despite not being approved for this purpose by the regulatory agencies, research has been conducted in people with MCI to determine whether biomarkers, such as <sup>18</sup>F‐flutemetamol for Aβ, increase the risk of developing dementia over time. The evidence for this is uncertain. For this and other reasons, the NIA‐AA in the USA established two different criteria for MCI. Firstly, they established the Core Clinical Criteria for use in all clinical settings, without use of biomarkers, and characterised by concerns regarding a change in cognition with impairment in one or more cognitive domains with preservation of independence in functional abilities, therefore no dementia. Secondly, they established the Clinical Research Criteria, which incorporate the use of biomarkers, such as PET amyloid scans, intended for use exclusively in research settings, including academic centres and clinical trials. This will help determine whether positive scans increase the likelihood of progression from MCI to clinical dementia (<a href="./references#CD012884-bbs2-0014" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2011;7(3):270‐9. ">Albert 2011</a>). Lastly, it is hoped that people with MCI and positive scans will 'enrich' clinical trials, and more people who will progress to dementia in a shorter time will be included to allow more efficient studies of treatments and prevention strategies of ADD (<a href="./references#CD012884-bbs2-0026" title="The Centers for Medicare &amp; Medicaid Services. Decision Memo for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG‐00431N). https://www.cms.gov/medicare‐coverage‐database/details/nca‐decision‐memo.aspx?NCAId=265 (accessed 08/10/2015). ">CMS 2013</a>). </p> <p>An assumption for some researchers, and one on which this systematic review (SR) is predicated, is that if a person has both MCI and the pathology of Alzheimer's disease and develops clinical ADD subsequently, then the cause of the initial MCI and of the ADD was the Alzheimer’s pathology. Our approach is an example of assessing diagnostic test accuracy (DTA) using delayed verification of diagnosis. Instead of the reference standard being based on pathology, it is based on a clinical standard and the progression from MCI to ADD, or any other form of non‐ADD, or any dementia. Although, for the reasons stated above, a degree of unreliability has been introduced, defining progression has the advantage of being based on what matters most to people with MCI, their families, and clinicians involved in their care. </p> <p><sup>18</sup>F‐flutemetamol PET scan is considered the diagnostic marker of interest, and in this SR we assessed the DTA of <sup>18</sup>F‐flutemetamol Aβ binding in the brain and progression of the following: </p> <p> <ul id="CD012884-list-0001"> <li> <p>From MCI to ADD.</p> </li> <li> <p>From MCI to any other form of non‐ADD.</p> </li> <li> <p>From MCI to any form of dementia</p> </li> </ul> </p> <p>This SR belongs to a series of SRs regarding PET biomarkers for Aβ, including <sup>18</sup>F‐florbetaben and <sup>18</sup>F‐florbetapir (<a href="./references#CD012884-bbs2-0063" title="MartínezG , FlickerL , VernooijRWM , Fuentes PadillaP , ZamoraJ , Roquéi Figuls M , et al. 18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD012216] ">Martínez 2016</a>). </p> <section id="CD012884-sec-0024"> <h3 class="title" id="CD012884-sec-0024">Target condition being diagnosed</h3> <p>This SR assessed the following three target conditions.</p> <p> <ul id="CD012884-list-0002"> <li> <p>ADD (progression from MCI to ADD).</p> </li> <li> <p>Any other form of dementia (progression from MCI to any other form of non‐ADD).</p> </li> <li> <p>Any form of dementia (progression from MCI to any form of dementia).</p> </li> </ul> </p> <p>We compared the index test results obtained at baseline with the results of the reference standards obtained at follow‐up (delayed verification). </p> </section> <section id="CD012884-sec-0025"> <h3 class="title" id="CD012884-sec-0025">Index test(s)</h3> <p>The <sup>18</sup>F‐flutemetamol scan is an index test for the detection of Aβ deposition in the brain region of interest (ROI). The ROI is a selected brain area that physicians create for further study in various anatomical areas of the brain. <sup>18</sup>F‐flutemetamol is a molecular biomarker, described as follows. </p> <p> <ul id="CD012884-list-0003"> <li> <p><sup>18</sup>F‐flutemetamol Aβ is described as 6‐benzothiazolol, 2‐[3‐[<sup>18</sup>F]fluoro‐4‐(methylamino)phenyl], and is also referred to as <sup>18</sup>F‐3'‐F‐6‐OH‐BTA1, <sup>18</sup>F‐GE067, AH110690 (<a href="./references#CD012884-bbs2-0059" title="KooleM , LewisDM , BuckleyC , NelissenN , VandenbulckeM , BrooksDJ , et al. Whole‐body biodistribution and radiation dosimetry of 18F‐GE067: a radioligand for in vivo brain amyloid imaging. Journal of Nuclear Medicine2009;50(5):818‐22. ">Koole 2009</a>; <a href="./references#CD012884-bbs2-0075" title="NelissenN , VanLaereK , ThurfjellL , OweniusR , VandenbulckeM , KooleM , et al. Phase 1 study of the Pittsburgh compound B derivative 18F‐flutemetamol in healthy volunteers and patients with probable Alzheimer disease. Journal of Nuclear Medicine2009;50(8):1251‐9. ">Nelissen 2009</a>). </p> </li> <li> <p><sup>18</sup>F‐flutemetamol has been evaluated in people with ADD, MCI, and healthy controls in a clinical field in order to identify a valid, simple, and reliable PET quantitation method for the routine measure of brain amyloid retention in vivo (<a href="./references#CD012884-bbs2-0100" title="VandenbergheR , VanLaereK , IvanoiuA , SalmonE , BastinC , TriauE , et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology2010;68(3):319‐29. ">Vandenberghe 2010</a>). </p> </li> </ul> </p> <p><b>Image Interpretation</b> </p> <p>Both the FDA and EMA have described the criteria for <sup>18</sup>F‐flutemetamol for Aβ positivity (<a href="./references#CD012884-bbs2-0036" title="European Medicines Agency. Vizamyl. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002557/WC500172950.pdf (accessed 8 April 2015). ">EMA 2014</a>; <a href="./references#CD012884-bbs2-0039" title="Food , DrugAdministration . Vizamyl. www.accessdata.fda.gov/drugsatfda_docs/label/2014/203137s002lbl.pdf (accessed 8 April 2015). ">FDA 2014</a>). </p> <p><sup>18</sup>F‐flutemetamol diagnosis is by PET image assessment, and is defined as positive if analysis shows the following. </p> <p> <ul id="CD012884-list-0004"> <li> <p>At least one cortical region (frontal lobes, posterior cingulate and precuneus, lateral temporal lobes, inferolateral parietal lobes, striatum) with reduction or loss of the normally distinct grey‐white matter contrast. These scans have one or more regions with increased cortical grey matter signal (above 50% to 60% peak intensity) or reduced (or absent) grey‐white matter contrast (white matter sulcal pattern is less distinct), or both. </p> </li> <li> <p>A positive scan may have one or more regions in which grey matter radioactivity is as intense or exceeds the intensity in adjacent white matter. </p> </li> </ul> </p> <p>Readers trained in PET images with the <sup>18</sup>F‐flutemetamol should interpret the Aβ PET images made with this ligand (<a href="./references#CD012884-bbs2-0036" title="European Medicines Agency. Vizamyl. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002557/WC500172950.pdf (accessed 8 April 2015). ">EMA 2014</a>; <a href="./references#CD012884-bbs2-0039" title="Food , DrugAdministration . Vizamyl. www.accessdata.fda.gov/drugsatfda_docs/label/2014/203137s002lbl.pdf (accessed 8 April 2015). ">FDA 2014</a>). </p> <p>Before the FDA and EMA described the criteria for <sup>18</sup>F‐flutemetamol scan positivity, the diagnosis of dementia was made using different thresholds. Therefore, we planned to use the FDA or EMA criteria applied in each included study to classify participants as either test‐positive or test‐negative, or, alternatively, if <sup>18</sup>F‐flutemetamol Aβ uptake and retention exceeded a certain threshold. </p> <p>We considered the measurement of the <sup>18</sup>F‐flutemetamol retention (retention ratio): distribution volume ratio (DVR), standardised uptake value ratio (SUVR), or other ratios. DVR refers to the ratio of the <sup>18</sup>F‐flutemetamol distribution volume in the selected area (ROI) to the distribution volume in the reference area. SUVR is the ratio of the <sup>18</sup>F‐flutemetamol ligand standardised uptake value in the selected area (ROI) to the standardised uptake value in the reference area. </p> <p>The unit of analysis of our SR was the participant. We did not include studies that analysed multiple ROIs per participant. </p> <p>Image analysis: not prespecified (e.g. Statistical Parametric Mapping (SPM) or other image analysis techniques). </p> <p><b>Administration Instructions and Recommended Dosing</b> </p> <p> <ul id="CD012884-list-0005"> <li> <p>Time between <sup>18</sup>F‐flutemetamol injection and PET acquisition: images should be acquired in 20 minutes starting from 90 minutes after intravenous administration (<a href="./references#CD012884-bbs2-0036" title="European Medicines Agency. Vizamyl. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002557/WC500172950.pdf (accessed 8 April 2015). ">EMA 2014</a>; <a href="./references#CD012884-bbs2-0039" title="Food , DrugAdministration . Vizamyl. www.accessdata.fda.gov/drugsatfda_docs/label/2014/203137s002lbl.pdf (accessed 8 April 2015). ">FDA 2014</a>). </p> </li> </ul> <ul id="CD012884-list-0006"> <li> <p>Injection dose: the recommended dose for <sup>18</sup>F‐flutemetamol Aβ PET is 185 MBq (5.0 mCi) administered as a single slow intravenous bolus (<a href="./references#CD012884-bbs2-0036" title="European Medicines Agency. Vizamyl. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002557/WC500172950.pdf (accessed 8 April 2015). ">EMA 2014</a>; <a href="./references#CD012884-bbs2-0039" title="Food , DrugAdministration . Vizamyl. www.accessdata.fda.gov/drugsatfda_docs/label/2014/203137s002lbl.pdf (accessed 8 April 2015). ">FDA 2014</a>). </p> </li> </ul> </p> <p>Although it was inevitable that included studies had used different imaging protocols, readers' expertise, and varied parameters, the amyloid PET data in these included studies should be technically adequate and acquired at a fully qualified and certified facility. </p> </section> <section id="CD012884-sec-0026"> <h3 class="title" id="CD012884-sec-0026">Clinical pathway</h3> <p>At this time, the clinical evaluation often has similarities between different countries (<a href="./references#CD012884-bbs2-0027" title="CordellaCB , BorsonS , BoustaniM , ChodoshJ , ReubenD , VergheseJ , et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2013;9(2):141‐50. ">Cordella 2013</a>; <a href="./references#CD012884-bbs2-0076" title="National Institute for Health Care Excellence. Dementia: supporting people with dementia and their carers in health and social care. NICE guidelines [CG42] Published date: November 2006. Last updated: April 2014. https://www.nice.org.uk/guidance/cg42 (accessed 17th April 2015). ">NICE 2006</a>). It often starts with people experiencing memory complaints detected by themselves or their relatives. Frequently, general practitioners or family physicians are consulted, and they often conduct a medical evaluation using a screening test for cognitive impairment. Whenever this screening test is positive, they complete an assessment with a clinical evaluation conducted with laboratory studies that can rule out a secondary cause of cognitive impairment (e.g. hypothyroidism, renal failure, liver failure, vitamin B12 or folate deficiency, and others). In addition, these people are then referred to medical specialists in cognitive disorders (preferably a geriatrician, psychiatrist, or neurologist) in a secondary centre or directly to memory clinics where further clinical assessment, laboratory studies, and cerebral image studies are conducted to confirm the dementia diagnosis. </p> <p>People with dementia, or their relatives, often directly consult these specialists or specialised memory clinics in the study of cognitive disorders. Therefore, the performance of the diagnostic tests will probably vary according to whether it is a primary consultation or referral from primary to specialist care, or if the people have different clinical stages of the disease (MCI, mild, moderate, or severe dementia). Due to these differing pathways, the use of <sup>18</sup>F‐flutemetamol PET ligand for Aβ is mainly used in specialist consultations and memory clinics as an addition to clinical evaluation or other tests, helping in a clinical setting to discard a diagnosis of Alzheimer's dementia with a negative scan in a person with clinical dementia and doubts about the aetiology (e.g. FTD versus ADD). Otherwise, it might be used solely in the research field in people with MCI for the enrichment of clinical trials, for example, enrolling people with MCI and a positive PET scan to study preventive interventions before people develop dementia. </p> <p>However, in some memory clinics the <sup>18</sup>F‐flutemetamol PET is used for clinical purposes in people with persistent or progressive unexplained MCI adopting the Johnson criteria (<a href="./references#CD012884-bbs2-0055" title="JohnsonKA , MinoshimaS , BohnenNI , DonohoeKJ , FosterNL , HerscovitchP , et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Journal of nuclear medicine : official publication, Society of Nuclear Medicine2013;54(3):476‐90. ">Johnson 2013</a>), criteria without sufficient evidence. Therefore, if the <sup>18</sup>F‐flutemetamol PET is positive in a person with MCI, this positivity is considered as one of the core histopathological findings of Alzheimer's disease. The person will thus be catalogued as a patient with prodromal Alzheimer's disease or MCI due to Alzheimer's disease. </p> <section id="CD012884-sec-0027"> <h4 class="title">Alternative test(s)</h4> <p>Currently there are no standard practice tests available for the clinical diagnosis of Alzheimer's disease dementia. Below, we have listed the alternative tests that we have excluded from this SR. The Cochrane Dementia and Cognitive Improvement Group is in the process of conducting a series of DTA SRs of biomarkers and scales (see list below). </p> <p> <ul id="CD012884-list-0007"> <li> <p><sup>18</sup>F PET ligands for Aβ (<sup>18</sup>F‐florbetapir, <sup>18</sup>F‐florbetaben) (<a href="./references#CD012884-bbs2-0063" title="MartínezG , FlickerL , VernooijRWM , Fuentes PadillaP , ZamoraJ , Roquéi Figuls M , et al. 18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD012216] ">Martínez 2016</a>). </p> </li> </ul> <ul id="CD012884-list-0008"> <li> <p><sup>18</sup>F‐FDG‐PET (PET F‐fluorodeoxyglucose) (<a href="./references#CD012884-bbs2-0097" title="SmailagicN , VacanteM , HydeC , MartinS , UkoumunneO , SachpekidisC . 18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2015, Issue 1. [DOI: 10.1002/14651858.CD010632.pub2] ">Smailagic 2015</a>). </p> </li> <li> <p>11C‐PIB‐PET (PET‐Pittsburgh compound B) (<a href="./references#CD012884-bbs2-0108" title="ZhangS , SmailagicN , HydeC , Noel‐StorrAH , TakwoingiY , McShaneR , et al. 11C‐PIB‐PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD010386.pub2] ">Zhang 2014</a>). </p> </li> <li> <p>Cerebrospinal fluid (CSF) analysis of Aβ and tau (<a href="./references#CD012884-bbs2-0058" title="KokkinouM , SmailagicN , Noel‐StorrAH , HydeC , UkoumunneO , WorrallRE , et al. Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD010945] ">Kokkinou 2014</a>; <a href="./references#CD012884-bbs2-0087" title="RitchieC , SmailagicN , LaddsEC , Noel‐StorrAH , UkoumunneO , MartinS . CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010803] ">Ritchie 2013</a>; <a href="./references#CD012884-bbs2-0088" title="RitchieC , SmailagicN , Noel‐StorrAH , TakwoingiY , FlickerL , MasonSE , et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2014, Issue 6. [DOI: 10.1002/14651858.CD008782.pub4] ">Ritchie 2014</a>). </p> </li> <li> <p>Structural magnetic resonance imaging (sMRI) (<a href="./references#CD012884-bbs2-0040" title="FilippiniG , CasazzaG , BellatorreAG , ListaC , DucaP , BeecherD , et al. The role of MRI in the early diagnosis of Alzheimer’s disease or other dementias in persons with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD009628] ">Filippini 2012</a>). </p> </li> <li> <p>Neuropsychological tests (Mini‐Mental State Examination (MMSE); MiniCOG; Montreal Cognitive Assessment (MoCA) (<a href="./references#CD012884-bbs2-0019" title="Arevalo‐RodriguezI , SmailagicN , Roquéi Figuls M , CiapponiA , Sanchez‐PerezE , GiannakouA , et al. Mini‐Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD010783.pub2] ">Arevalo‐Rodriguez 2015</a>; <a href="./references#CD012884-bbs2-0025" title="ChanCCH , FageBA , SmailagicN , GillSS , HerrmannN , NikolaouV , et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care setting. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD011414] ">Chan 2014</a>; <a href="./references#CD012884-bbs2-0028" title="CreavinS , WisniewskiS , Noel‐StorrA , TrevelyanC , HamptonT , RaymentD , et al. Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD011145.pub2] ">Creavin 2016</a>; <a href="./references#CD012884-bbs2-0030" title="DavisDHJ , CreavinST , YipJLY , Noel‐StorrAH , BrayneC , CullumS . Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementias. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD010775.pub2] ">Davis 2015</a>; <a href="./references#CD012884-bbs2-0038" title="FageBA , ChanCCH , GillSS , Noel‐StorrAH , HerrmannN , SmailagicN , et al. Mini‐Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD010860.pub2] ">Fage 2015</a>; <a href="./references#CD012884-bbs2-0094" title="SeitzDP , FageBA , ChanCCH , GillSS , HerrmannN , SmailagicN , et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a primary care setting. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD011415] ">Seitz 2014</a>). </p> </li> <li> <p>Informant interviews (Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE); AD8) (<a href="./references#CD012884-bbs2-0046" title="HarrisonJK , FearonP , Noel‐StorrAH , McShaneR , StottDJ , QuinnTJ . Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD010771.pub2] ">Harrison 2014</a>; <a href="./references#CD012884-bbs2-0048" title="HendryK , LeesRA , McShaneR , Noel‐StorrAH , StottDJ , QuinnTJ . AD‐8 for diagnosis of dementia across a variety of healthcare settings. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD011121] ">Hendry 2014</a>; <a href="./references#CD012884-bbs2-0060" title="LeesRA , StottDJ , McShaneR , Noel‐StorrAH , QuinnTJ . Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD011333] ">Lees 2014</a>; <a href="./references#CD012884-bbs2-0047" title="HarrisonJK , FearonP , Noel‐StorrAH , McShaneR , StottDJ , QuinnTJ . Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD010772.pub2] ">Harrison 2015</a>; <a href="./references#CD012884-bbs2-0083" title="QuinnTJ , FearonP , Noel‐StorrAH , YoungC , McShaneR , StottDJ . Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD010079.pub2] ">Quinn 2014</a>). </p> </li> <li> <p>APOE‐ϵ4 (<a href="./references#CD012884-bbs2-0033" title="Elias‐SonnenscheinLS , ViechtbauerW , RamakersI , UkoumunneO , VerheyFRJ , VisserPJ . APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community setting. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD010948] ">Elias‐Sonnenschein 2014a</a>; <a href="./references#CD012884-bbs2-0034" title="Elias‐SonnenscheinLS , ViechtbauerW , RamakersI , UkoumunneO , VerheyFRJ , VisserPJ . APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care setting. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD010949] ">Elias‐Sonnenschein 2014b</a>; <a href="./references#CD012884-bbs2-0035" title="Elias‐SonnenscheinLS , ViechtbauerW , RamakersI , UkoumunneO , VerheyFRJ , VisserPJ . APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care setting. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD010950] ">Elias‐Sonnenschein 2014c</a>). </p> </li> <li> <p>Single‐photon emission computed tomography (SPECT) brain imaging (<a href="./references#CD012884-bbs2-0018" title="ArcherHA , SmailagicN , JohnC , HolmesRB , TakwoingiY , CoulthardEJ , et al. Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal dementia in people with suspected dementia. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD010896.pub2] ">Archer 2015</a>; <a href="./references#CD012884-bbs2-0066" title="McCleeryJ , MorganS , BradleyKM , Noel‐StorrAH , AnsorgeO , HydeC . Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database of Systematic Reviews2015, Issue 1. [DOI: 10.1002/14651858.CD010633.pub2] ">McCleery 2015</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012884-sec-0028"> <h3 class="title" id="CD012884-sec-0028">Rationale</h3> <p>Accurate and early diagnosis of Alzheimer's disease is crucial for planning in healthcare systems, because the costs of dementia are currently at least 1% of the world's GNP (<a href="./references#CD012884-bbs2-0105" title="World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. 2012. http://www.who.int/mental_health/publications/dementia_report_2012/en/. World Health Organization, (accessed 23th September 2015). ">WHO 2012</a>). </p> <p><sup>18</sup>F‐flutemetamol is approved for use in the clinical field mainly in people who are diagnosed clinically with dementia of uncertain aetiology, in which case diagnosis of ADD can be discarded if the test is negative. Even though <sup>18</sup>F‐flutemetamol is not approved for this purpose, this biomarker test is currently being used in the research field to search for the accurate identification of people with MCI who would progress to ADD or other forms of dementia. Amyloid β tracers by PET have been included in newly diagnostic criteria in the study in people with MCI (<a href="./references#CD012884-bbs2-0014" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2011;7(3):270‐9. ">Albert 2011</a>; <a href="./references#CD012884-bbs2-0032" title="DuboisB , FeldmanHH , JacovaC , HampelH , MolinuevoJL , BlennowK , et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG‐2 criteria. The Lancet. Neurology2014;13(6):614‐29. ">Dubois 2014</a>). However, some uncertainties exist about the generalisability of the DTA results in clinical settings, especially in older people (<a href="./references#CD012884-bbs2-0086" title="RichardE , SchmandB , EikelenboomP , WestendorpRG , VanGoolWA . The Alzheimer myth and biomarker research in dementia. Journal of Alzheimer's Disease: JAD2012;31(Suppl 3):S203‐9. ">Richard 2012</a>). </p> <p>It is currently believed that if the health system can identify which people are at high risk of progressing from MCI to dementia, it can focus on improving opportunities for appropriate contingency planning for them. Proper recognition of the disease may also help prevent inappropriate and potentially harmful admissions to hospital or institutional care (<a href="./references#CD012884-bbs2-0073" title="National Audit Office. Improving services and support for people with dementia. Report by the Comptroller and Auditor General. HC 604 Session General 2006‐2007. 4 July 2007. https://www.nao.org.uk/wp‐content/uploads/2007/07/0607604.pdf (accessed 25th March 2015). ">NAO 2007</a>), and enable the development of new treatments designed to delay or prevent progression to more debilitating stages of the disease. Additionally, this may demonstrate a real clinical benefit for people and caregivers, and will reduce health system costs. </p> <p>This SR assesses the DTA with <sup>18</sup>F‐flutemetamol Aβ PET in people with MCI. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012884-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012884-sec-0029"></div> <p>To determine the diagnostic test accuracy (DTA) of <sup>18</sup>F‐flutemetamol as the index test for detecting people with mild cognitive impairment (MCI) at time of performing the test who would clinically progress to Alzheimer's disease dementia (ADD), or other forms of non‐ADD, or any form of dementia at follow‐up. </p> <section id="CD012884-sec-0030"> <h3 class="title" id="CD012884-sec-0030">Secondary objectives</h3> <p>To investigate the heterogeneity of the DTA in the included studies, by evaluating the spectrum of people, referral centres, clinical criteria of MCI, <sup>18</sup>F‐flutemetamol techniques, reference standards used, duration of follow‐up, aspects of study quality, and conflicts of interest. </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012884-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012884-sec-0031"></div> <section id="CD012884-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012884-sec-0033"> <h4 class="title">Types of studies</h4> <p>We included longitudinal studies that had prospectively defined cohorts with any accepted definition of mild cognitive impairment (MCI), as outlined below, at time of performing the <sup>18</sup>F‐flutemetamol Aβ scan and a reference standard (see <a href="#CD012884-sec-0035">Index tests</a> and <a href="#CD012884-sec-0037">Reference standards</a> below). We obtained the results at the follow‐up of the studies. These studies had to employ delayed verification of progression to dementia and were sometimes labelled as 'delayed verification cross sectional studies' (<a href="./references#CD012884-bbs2-0020" title="BossuytPM , LeeflangMM . Chapter 6: Developing criteria for including studies. In: Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4 [updated September 2008]. The Cochrane Collaboration, 2008. http://methods.cochrane.org/sdt/sites/methods.cochrane.org.sdt/files/uploads/Chapter06‐Including‐Studies%20(September‐2008).pdf. The Cochrane Collaboration. ">Bossuyt 2008</a>; <a href="./references#CD012884-bbs2-0056" title="KnottnerusJA , vanWeelC , MurisJW . Evaluation of diagnostic procedures. BMJ2002;324(7335):477‐80. ">Knottnerus 2002</a>). We included case‐control studies when they incorporate a delayed verification design. This occurred in the context of a cohort study, so these studies were invariably diagnostic‐nested case‐control studies. </p> </section> <section id="CD012884-sec-0034"> <h4 class="title">Participants</h4> <p>Participants recruited and clinically classified as having MCI at time of performing the test were eligible for inclusion. We established the diagnosis of MCI using the Petersen criteria or revised Petersen criteria (<a href="./references#CD012884-bbs2-0080" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999;56(3):303‐8. ">Petersen 1999</a>; <a href="./references#CD012884-bbs2-0081" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004;256(3):183‐94. ">Petersen 2004</a>; <a href="./references#CD012884-bbs2-0106" title="WinbladB , PalmerK , KivipeltoM , JelicV , FratiglioniL , WahlundLO , et al. Mild cognitive impairment‐‐beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine2004;256(3):240‐6. ">Winblad 2004</a>), the criteria included in Matthews study (<a href="./references#CD012884-bbs2-0064" title="MatthewsFE , StephanBC , McKeithIG , BondJ , BrayneC , Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008;56(8):1424‐33. ">Matthews 2008</a>), CDR = 0.5 (CDR structured interviews collects information from both the collateral source and the subject regarding memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care, where the range of possible scores varies from none=0 point to severe=3 points) (<a href="./references#CD012884-bbs2-0072" title="MorrisJC . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology1993;43(11):2412‐4. ">Morris 1993</a>), the National Institute on Aging‐Alzheimer's Association (NIA‐AA) core clinical criteria (<a href="./references#CD012884-bbs2-0014" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia: the Journal of the Alzheimer's Association2011;7(3):270‐9. ">Albert 2011</a>), or a combination. </p> <p>We excluded studies that included people with MCI possibly caused by any of the following:</p> <p> <ul id="CD012884-list-0009"> <li> <p>Current or a history of alcohol or drug abuse.</p> </li> <li> <p>Central nervous system (CNS) trauma (e.g. subdural hematoma), tumour, or infection.</p> </li> <li> <p>Other neurological conditions (e.g. Parkinson’s or Huntington’s diseases). Regarding Parkinson's disease, many of the studies specifically excluded people with Parkison's disease from the group with mild cognitive impairment. This specific group of people is complex in both regards to defining neuropathology and in determination of functional decline. For these reasons this group of people needs to be addressed in specific studies </p> </li> </ul> </p> </section> <section id="CD012884-sec-0035"> <h4 class="title">Index tests</h4> <p>The index test of this SR was <sup>18</sup>F‐flutemetamol biomarker test. We used the criteria and cut‐off values for test positivity, as reported in the included studies. We considered positivity for <sup>18</sup>F‐flutemetamol Aβ scan uptake and retention exceeding a certain threshold. </p> </section> <section id="CD012884-sec-0036"> <h4 class="title">Target conditions</h4> <p>Three target conditions were included in this SR:</p> <p> <ul id="CD012884-list-0010"> <li> <p>Alzheimer’s disease dementia (ADD) (progression from MCI to ADD).</p> </li> <li> <p>Any other forms of dementia (progression from MCI to any other forms of non‐ADD).</p> </li> <li> <p>Any form of dementia (progression from MCI to any form of dementia).</p> </li> </ul> </p> </section> <section id="CD012884-sec-0037"> <h4 class="title">Reference standards</h4> <p>The reference standard was the progression to the target conditions evaluated by a physician with expertise in the dementia field (preferably a geriatrician, psychiatrist, or neurologist). For the purpose of this SR, we accepted several definitions of ADD. We included studies that applied the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDSADRDA) criteria (<a href="./references#CD012884-bbs2-0069" title="McKhannGM , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>), the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria (<a href="./references#CD012884-bbs2-0016" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987. ">APA 1987</a>; <a href="./references#CD012884-bbs2-0017" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>), and the International Classification of Diseases (ICD) (<a href="./references#CD012884-bbs2-0052" title="World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD‐10 Version:2010). http://apps.who.int/classifications/icd10/browse/2010/en (accessed 29 January 2015). ">ICD‐10</a>) criteria for ADD. Notably, different iterations of these standards may not be directly comparable over time (e.g. <a href="./references#CD012884-bbs2-0016" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987. ">APA 1987</a> versus <a href="./references#CD012884-bbs2-0017" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>). Moreover, the validity of the diagnoses may vary with the degree or manner in which the criteria have been operationalised (e.g. individual clinician versus algorithm versus consensus determination). We considered all these issues when we interpreted the results. </p> <p>Similarly, we accepted differing clinical definitions of other dementias. For Lewy Body Dementia the reference standard is the McKeith criteria (<a href="./references#CD012884-bbs2-0067" title="McKeithIG , GalaskoD , KosakaK , PerryEK , DicksonDW , HansenLA , et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996;47(5):1113‐24. ">McKeith 1996</a>; <a href="./references#CD012884-bbs2-0068" title="McKeithIG , DicksonDW , LoweJ , EmreM , O'BrienJT , FeldmanH , et al for the Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology2005;65(12):1863‐72. ">McKeith 2005</a>); for frontotemporal dementia the Lund criteria (<a href="./references#CD012884-bbs2-0021" title="BoxerAL , MillerBL . Clinical features of frontotemporal dementia. Alzheimer Disease and Associated Disorders2005;19(Suppl 1):S3‐6. ">Boxer 2005</a>; <a href="./references#CD012884-bbs2-0022" title="BrunA , EnglundB , GustafsonL , PassantU , MannDMA , NearyD , et al. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. Journal of Neurology, Neurosurgery, and Psychiatry1994;57(4):416‐8. ">Brun 1994</a>; <a href="./references#CD012884-bbs2-0074" title="NearyD , SnowdenJS , GustafsonL , PassantU , StussD , BlackS , et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology1998;51(6):1546‐54. ">Neary 1998</a>), the DSM criteria (<a href="./references#CD012884-bbs2-0016" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987. ">APA 1987</a>; <a href="./references#CD012884-bbs2-0017" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>), the ICD criteria (<a href="./references#CD012884-bbs2-0052" title="World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD‐10 Version:2010). http://apps.who.int/classifications/icd10/browse/2010/en (accessed 29 January 2015). ">ICD‐10</a>), or the International Behavioural Variant FTD Criteria Consortium (<a href="./references#CD012884-bbs2-0084" title="RascovskyK , HodgesJR , KnopmanD , MendezMF , KramerJH , NeuhausJ , et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain: a Journal of Neurology2011;134(Pt 9):2456‐77. ">Rascovsky 2011</a>); and, for vascular dementia, the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences (NINDS‐AIREN) criteria (<a href="./references#CD012884-bbs2-0089" title="RománGC , TatemichiTK , ErkinjunttiT , CummingsJL , MasdeuJC , GarciaJH , et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop. Neurology1993;43(2):250‐60. ">Román 1993</a>), the DSM criteria (<a href="./references#CD012884-bbs2-0016" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987. ">APA 1987</a>; <a href="./references#CD012884-bbs2-0017" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>), or the ICD criteria (<a href="./references#CD012884-bbs2-0052" title="World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD‐10 Version:2010). http://apps.who.int/classifications/icd10/browse/2010/en (accessed 29 January 2015). ">ICD‐10</a>). </p> <p>The time interval in which the progression from MCI to ADD (or other forms of dementia) occurs is very important. We used one year as the minimum period of delay in the verification of the diagnosis (the time between the assessment at which a diagnosis of MCI is made and the assessment at which the diagnosis of dementia is made). </p> </section> </section> <section id="CD012884-sec-0038"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012884-sec-0039"> <h4 class="title">Electronic searches</h4> <p>We searched MEDLINE (Ovid SP) from 1946 to May 2017; Embase (Ovid SP) from 1974 to May 2017; PsycINFO (Ovid SP) from 1806 to May 2017; BIOSIS Citation Index (Thomson Reuters Web of Science) from 1922 to May 2017; Web of Science Core Collection, including the Science Citation Index (Thomson Reuters Web of Science) and the Conference Proceedings Citation Index (Thomson Reuters Web of Science) from 1946 to May 2017; LILACS (Bireme); CINAHL (EBSCOhost) from 1980 to May 2017; ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">https://clinicaltrials.gov</a>); and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">http://www.who.int/ictrp/search/en/</a>). We also searched ALOIS, the Cochrane Dementia &amp; Cognitive Improvement Group’s specialized register of dementia studies (<a href="http://www.medicine.ox.ac.uk/alois/" target="_blank">http://www.medicine.ox.ac.uk/alois/</a>). </p> <p>We used two approaches in designing the search. One focused solely on the specifically named index test (including a range of synonyms) and the second, run in parallel covered a more general search, linking broader terms for the index test. It focused on terms describing its diagnostic use and terms for the target condition to try to capture the more difficult to locate studies of a more general nature, where these particular radioligands were included in diagnostic accuracy research but not named specifically in the parts of the electronic bibliographic record that are searchable and therefore would be missed. </p> <p>See <a href="./appendices#CD012884-sec-0064">Appendix 2</a> for details of the sources and search strategies that we used. No language or date restrictions were applied to the electronic searches. </p> </section> <section id="CD012884-sec-0040"> <h4 class="title">Searching other resources</h4> <p>We examined the reference lists of all relevant studies for additional studies. We also searched the Database of Abstracts of Reviews of Effects (DARE) via the Cochrane Library (<a href="http://www.cochranelibrary.com" target="_blank">www.cochranelibrary.com</a>)), the National Institute for Health Research ‐ Health Technology Assessment Database (NIHR‐HTA) (via the Cochrane Library: <a href="http://www.cochranelibrary.com" target="_blank">www.cochranelibrary.com</a>), the Aggressive Research Intelligence Facility (ARIF) database (<a href="http://www.arif.bham.ac.uk/" target="_blank">www.arif.bham.ac.uk</a>) for other related systematic diagnostic accuracy reviews, and the International Federation of Clinical Chemistry and Laboratory Medicine Committee for Evidence‐based Laboratory Medicine database (C‐EBLM) (<a href="http://www.ifcc.org/ifcc-education-division/emd-committees/c-eblm/evidence-based-laboratory-medicine-c-eblm-base" target="_blank">http://www.ifcc.org/ifcc‐education‐division/emd‐committees/c‐eblm/evidence‐based‐laboratory‐medicine‐c‐eblm‐base</a>). </p> <p>We checked the reference lists of any relevant studies and SRs, and performed citation tracking using the Science Citation Index to identify any additional relevant studies. </p> </section> </section> <section id="CD012884-sec-0041"> <h3 class="title" id="CD012884-sec-0041">Data collection and analysis</h3> <section id="CD012884-sec-0042"> <h4 class="title">Selection of studies</h4> <p>Two review authors (GM, RV) independently screened the retrieved titles and abstracts for potentially eligible studies. A third review author (PF) resolved any disagreements between the two review authors. The two review authors (GM, RV) then independently assessed the full‐text articles of the selected studies with the inclusion criteria. They resolved any disagreements through discussion or, where necessary, consulted a third review author (PF) who acted as an arbitrator. When a study did not present all relevant data for creating 2 × 2 table, we contacted the study authors directly to request further information. When more than one article presented data on the same population, we included the primary article, which was the article with the largest number of people or with the most informative data (e.g. longest time of follow‐up in the primary outcome). </p> </section> <section id="CD012884-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>We planned to extract the following data regarding the study characteristics.</p> <p> <ul id="CD012884-list-0011"> <li> <p>Bibliographic details of primary paper:</p> <ul id="CD012884-list-0012"> <li> <p>author, title of study, year, and journal.</p> </li> </ul> </li> <li> <p>Basic clinical and demographic details:</p> <ul id="CD012884-list-0013"> <li> <p>number of participants;</p> </li> <li> <p>clinical diagnosis;</p> </li> <li> <p>MCI clinical criteria;</p> </li> <li> <p>age;</p> </li> <li> <p>gender;</p> </li> <li> <p>sources of referral;</p> </li> <li> <p>participant recruitment;</p> </li> <li> <p>sampling procedures.</p> </li> </ul> </li> <li> <p>Details of the index test:</p> <ul id="CD012884-list-0014"> <li> <p>method of the <sup>18</sup>F‐flutemetamol test administration, including those who administered the test; </p> </li> <li> <p>thresholds used to define positive and negative test;</p> </li> <li> <p>other technical aspects as seemed relevant to the review, e.g. brain areas.</p> </li> </ul> </li> <li> <p>Details of the reference standard:</p> <ul id="CD012884-list-0015"> <li> <p>definition of ADD and other dementias used in reference standard;</p> </li> <li> <p>duration of follow‐up from time of the index test performed to defining ADD and other dementias by the reference standard: one year to less than two years; two years to less than four years; and four years or more. If participants had been followed for varied amounts of time we recorded a mean follow‐up period for each included study. If possible, we grouped those data into minimum, maximum, and median follow‐up periods, to enable subgroup analyses; </p> </li> <li> <p>prevalence or proportion of population developing ADD and other dementias, with severity if described. </p> </li> </ul> </li> </ul> </p> <p>We created 2 × 2 tables (cross‐relating index test results of the reference standards) as shown in <a href="./appendices#CD012884-sec-0065">Appendix 3</a>. For each included study, we recorded the number of participants lost to follow‐up. We also extracted data necessary for the quality assessment, as defined below. Two review authors (GM, RV) independently performed data extraction. We resolved any disagreements regarding data extraction by discussion, or consulting a third review author (PF), if it was necessary. </p> </section> <section id="CD012884-sec-0044"> <h4 class="title">Assessment of methodological quality</h4> <p>We assessed the methodological quality of the included studies using the Quality Assessment of Diagnostic Accuracy Studies 2 tool (QUADAS‐2) (<a href="./references#CD012884-bbs2-0104" title="WhitingPF , RutjesAWS , WestwoodME , MalletS , DeeksJJ , ReitsmaJB . QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529‐36. ">Whiting 2011</a>), as recommended by Cochrane (<a href="./references#CD012884-bbs2-0029" title="DavisDHJ , CreavinST , Noel‐StorrA , QuinnTJ , SmailagicN , HydeC , et al. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010460] ">Davis 2013</a>). This tool is comprised of four domains: patient selection, index test, reference standard, and patient flow.<br/> <br/> Two review authors (GM, RV), who were blinded to each other’s scores, independently performed the QUADAS‐2 assessment. We resolved any disagreements by discussion or, if necessary, consulted a third review author (PF) who acted as an arbitrator. We assessed each domain in terms of risk of bias, and also considered the first three domains in terms of applicability concerns. In <a href="./appendices#CD012884-sec-0066">Appendix 4</a>, we have detailed the components of each of these domains and provided a rubric that shows how we made judgements concerning risk of bias. Key areas important to quality assessment were participant selection, blinding, and missing data. </p> <p>We included three additional signalling questions on our checklist.</p> <p> <ul id="CD012884-list-0016"> <li> <p>Was the PET scan interpretation done by a trained reader physician? (We included this under the ’Index test’ domain.) </p> </li> <li> <p>Was there a clear definition of a positive result? (We included this under the ’Index test’ domain.) </p> </li> <li> <p>Was the study free of commercial funding? (We included this under the ’flow and timing’ domain.) </p> </li> </ul> </p> <p>We included the item pertaining to the PET scan interpretation and the definition of positive results to take into account the subjective nature of the <sup>18</sup>F‐flutemetamol Aβ scan image interpretation, which may be based on a variety of different criteria, such as extensive clinical experience, different standardised uptake values (SUV), different morphological features, or a combination of the aforementioned. We included the third additional item in order to record any potential bias resulting from commercial interest in the results due to the potential risk by the manufacturing company leading to more favourable results and conclusions than sponsorship by other sources (<a href="./references#CD012884-bbs2-0061" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). </p> <p>We did not use QUADAS‐2 data to form a summary quality score. We produced a narrative summary that described each included study as at high, low, or unclear risk of bias, as well as concerns regarding applicability, which we have described in <a href="./appendices#CD012884-sec-0067">Appendix 5</a>. </p> </section> <section id="CD012884-sec-0045"> <h4 class="title">Statistical analysis and data synthesis</h4> <p>We applied the DTA framework for the analysis of a single test and extracted the data from each included study into a 2×2 table, showing the binary test results cross‐classified with the binary reference standard, and we ignored any censoring that might have occurred. We acknowledge that such a reduction in the data may represent a significant oversimplification. We used data from the 2×2 tables abstracted from the included studies: true positive (TP), false negative (FN), false positive (FP), true negative (TN), and entered these into Review Manager (RevMan) (<a href="./references#CD012884-bbs2-0085" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>) to calculate the sensitivities, specificities, and their 95% confidence intervals. We also presented individual study results graphically by plotting estimates of sensitivities and specificities in both a forest plot. If an individual included study published more than one threshold, we presented the graphical findings for all reported thresholds. </p> <p>We planned to segment analyses into separate follow‐up mean periods for the delay in verification: one year to less than two years; two to less than four years; and greater than four years. In this we planned to clearly note where the same included studies contributed to the analysis for more than one reference standard follow‐up interval. </p> <p>However, due to lack of data, we conducted no meta‐analyses. However, we prepared a 'summary of findings table'. </p> </section> <section id="CD012884-sec-0046"> <h4 class="title">Investigations of heterogeneity</h4> <p>We were able to include only two studies, therefore issues of heterogeneity did not arise. </p> </section> <section id="CD012884-sec-0047"> <h4 class="title">Sensitivity analyses</h4> <p>We found insufficient data to conduct any sensitivity analyses.</p> </section> <section id="CD012884-sec-0048"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not investigate reporting bias.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012884-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012884-sec-0049"></div> <section id="CD012884-sec-0050"> <h3 class="title" id="CD012884-sec-0050">Results of the search</h3> <p>The total number of records identified for this SR was 1333. The PRISMA diagram (<a href="#CD012884-fig-0001">Figure 1</a>) shows the selection of records through the screening and selection processes. In total, we assessed 81 studies (23 full‐text papers, 22 conference publications, 11 registered studies in clinicaltrials.gov, and 25 registered studies in WHO ICTRP) for eligibility in the full‐text screening. We excluded 72 studies. Ten studies were multiple publications or duplicated and 4 studies did not have extractable data for constructing 2 x 2 tables, and we received no reply when we contacted the authors (<a href="./references#CD012884-bbs2-0003" title="GoukasianN , LeClairH , PoratS , HwangKS , RingmanJM , SilvermanD , et al. Anxiety is associated with brain amyloidosis in cognitively normal and mild cognitive impairment subjects: a [18f] flutemetamol PET study. Alzheimer's &amp; Dementia2015;11(7 Suppl):17. ">Goukasian 2015</a>; <a href="./references#CD012884-bbs2-0004" title="RoweCC , DoreV , BourgeatP , BrownBM , ThurfjellL , MacaulayL , et al. Abeta accumulation in non‐demented individuals: a longitudinal F‐18‐flutemetamol study. Alzheimer's &amp; Dementia. 2015; Vol. 11:125. ">Rowe 2015a</a>; <a href="./references#CD012884-bbs2-0005" title="RoweCC , DoreV , BourgeatP , ThurfjellL , MacaulayL , WilliamsR , et al. Longitudinal assessment of abeta accumulation in non‐demented individuals: a 18F‐flutemetamol study. Neuro‐degenerative Diseases2015;15 Suppl 1:904. ">Rowe 2015b</a>; <a href="./references#CD012884-bbs2-0006" title="RoweC , DoreV , BourgeatP , ThurfjellL , MacaulayS , WilliamsR , et al. Longitudinal assessment of Abeta accumulation in non‐demented individuals: a 18F‐flutemetamol study. Journal of Nuclear Medicine2015;56:193. ">Rowe 2015c</a>) (<a href="./references#CD012884-sec-0076" title="">Characteristics of excluded studies</a>). We excluded the remaining 58 studies because they did not meet the inclusion criteria: i) not a longitudinal study (n = 23); ii) no MCI participants at time of performing the test (n = 21); iii) index test not a <sup>18</sup>F‐flutemetamol PET scan (n = 4); iv) discussion or review paper (n = 6); v) wrong outcomes or design (n = 4). We included two studies and identified seven references as ongoing studies. </p> <div class="figure" id="CD012884-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD012884-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_n/nCD012884-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> <p><b>Included studies</b> </p> <p>See <a href="./references#CD012884-sec-0075" title="">Characteristics of included studies</a>. </p> <p><a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a> refers to a study with baseline data that had been published 2 years earlier with ADD, MCI and healthy controls (HC) participants. MCI participants were recruited from secondary care (7 memory clinics). Participants were recruited as part of a study to evaluate the <sup>18</sup>F‐flutemetamol PET scan in people with ADD (n = 27), amnestic MCI (n = 20) and healthy controls (n = 20) as a cross‐sectional study to determine the efficacy of blinded visual assessment of images of <sup>18</sup>F‐flutemetamol uptake for separating subjects with clinically probable ADD from healthy controls, the SUVRs of subjects with probable ADD and HC, the concordance between (11)C‐labelled Pittsburgh Compound‐B ((11)C‐PIB) and <sup>18</sup>F‐flutemetamol scans, regarding visual assessment and quantitative SUVR in ADD and MCI participants, and the assignation of a raised or low amyloid group category through visual or quantitative assessment in MCI participants (<a href="./references#CD012884-bbs2-0100" title="VandenbergheR , VanLaereK , IvanoiuA , SalmonE , BastinC , TriauE , et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology2010;68(3):319‐29. ">Vandenberghe 2010</a>). </p> <p>The study of Thurfjell 2012 included 20 MCI participants with a follow‐up of two years to evaluate the progression from amnestic MCI to probable ADD according to their <sup>18</sup>F‐flutemetamol status as positive or negative, using a SUVR &gt; 1.5 (<a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a>). The SUVR established in the previous study with ADD and HC participants was 1.56. The other objective of this study was to compute the hippocampus volume from MRI and investigate its accuracy performance alone and combined with the <sup>18</sup>F‐flutemetamol PET scan at follow‐up. MCI participants fulfilled <a href="./references#CD012884-bbs2-0080" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999;56(3):303‐8. ">Petersen 1999</a> criteria for amnestic MCI, 11 were male, they had a mean age of 72.7 + 7.09 years, with 14.4 + 2.97 mean years of education, and their mean MMSE was 28.0 + 0.94 points. </p> <p>Of the 20 participants, 9 (45%) developed Alzheimer’s dementia. One participant (5%) was reported as lost to follow‐up without further information about the cause. </p> <p>The reference standard was not explicitly stated, although NINCDS‐ADRDA criteria for ADD (<a href="./references#CD012884-bbs2-0069" title="McKhannGM , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>) and <a href="./references#CD012884-bbs2-0017" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a> were baseline diagnostic criteria in the Vandenberghe study (<a href="./references#CD012884-bbs2-0100" title="VandenbergheR , VanLaereK , IvanoiuA , SalmonE , BastinC , TriauE , et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology2010;68(3):319‐29. ">Vandenberghe 2010</a>). </p> <p>Potential conflicts of interest were noted. Financial support for the baseline study (<a href="./references#CD012884-bbs2-0100" title="VandenbergheR , VanLaereK , IvanoiuA , SalmonE , BastinC , TriauE , et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology2010;68(3):319‐29. ">Vandenberghe 2010</a>) was from the manufacturer of <sup>18</sup>F‐flutemetamol tracer and two authors were employees of this company. </p> <p><a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a> refers to an international and multicentric study in the United States and Europe (also known as EUCTR2009‐010227‐62‐GB in Europe) and with a common sponsor's protocol code number, GE‐067‐005. </p> <p>The main objective of this study was to evaluate the 'hazard ratio by PET scan readers for conversion to probable Alzheimer's disease based on visual image Interpretation' in amnestic MCI participants with normal and abnormal patterns of <sup>18</sup>F‐flutemetamol uptake, based on the visual assessment of a <sup>18</sup>F‐flutemetamol PET scan. This unpublished study had no information regarding the participants' recruitment. There were 230 planned evaluable participants. The participants were 60 years old or older (US inclusion criteria in clinicaltrials.gov) or over 55 years old (Europe in EUDRACT), they met the Petersen criteria for amnestic MCI (not provided which of the different Petersen criteria published were used), had a score of less than or equal to 4 on the Modified Hachinski Ischemic Scale, a MMSE score of 24 to 30, and a non‐contrast MRI examination as part of the screening visit that excluded amnestic MCI arising from structural causes, and they had no significant neurologic disease other than suspected amnestic MCI. The mean age was 71.1 (+ 8.62) years, 63 participants were less than 65 years, and 118 were women. </p> <p>Participants were assessed clinically on‐site every six months until progression to probable ADD (as determined by an independent Clinical Adjudication Committee (CAC)); or completion of 36 months of follow‐up, whichever came first. Clinical assessments were performed by a trained on‐site clinician who collected the results of a battery of tests, the National Institute of Neurological and Communicative Disorders and Stroke‐Alzheimer’s Disease and Related Disorders Association (NINCDS‐ADRDA) diagnostic criteria for probable ADD, and clinical assessment; this clinician was blinded to the subjects’ PET images and interpretations until the study was complete. The follow‐up data were regularly submitted to the CAC (which consisted of four experts in the diagnosis of memory disorders), which determined whether or not the subject had converted to probable ADD. The CAC reviewed all study data (excluding the investigator’s progression assessment, the <sup>18</sup>F‐flutemetamol PET scan results and any other amyloid imaging data) for each subject to determine whether or not the subject had converted to probable ADD. The decision rules to be used in defining a progression to probable ADD were established by the CAC before reviewing any subject’s data. </p> <p>The study analysed 224 participants of the original 232 participants at 36 months of follow‐up, because 8 participants withdrew before the first assessment at the follow‐up. </p> <p>Potential conflicts of interest were noted. Total financial support was provided from the manufacturer of <sup>18</sup>F‐flutemetamol tracer. </p> <p><b>Excluded studies</b> </p> <p>We excluded four studies since they did not meet the inclusion criteria for participants, index test, or target condition (<a href="./references#CD012884-sec-0076" title="">Characteristics of excluded studies</a>). </p> <p>The <a href="./references#CD012884-bbs2-0003" title="GoukasianN , LeClairH , PoratS , HwangKS , RingmanJM , SilvermanD , et al. Anxiety is associated with brain amyloidosis in cognitively normal and mild cognitive impairment subjects: a [18f] flutemetamol PET study. Alzheimer's &amp; Dementia2015;11(7 Suppl):17. ">Goukasian 2015</a> study was focused on neuropsychiatric symptoms with a probable follow‐up in 38 MCI participants with a SUVR &gt; 1.27 for brain amyloidosis. In <a href="./references#CD012884-bbs2-0004" title="RoweCC , DoreV , BourgeatP , BrownBM , ThurfjellL , MacaulayL , et al. Abeta accumulation in non‐demented individuals: a longitudinal F‐18‐flutemetamol study. Alzheimer's &amp; Dementia. 2015; Vol. 11:125. ">Rowe 2015a</a>, there were 59 participants with MCI at the time of performing the test and at the end of 18 months of follow‐up, there were 16 participants to be evaluated. In <a href="./references#CD012884-bbs2-0005" title="RoweCC , DoreV , BourgeatP , ThurfjellL , MacaulayL , WilliamsR , et al. Longitudinal assessment of abeta accumulation in non‐demented individuals: a 18F‐flutemetamol study. Neuro‐degenerative Diseases2015;15 Suppl 1:904. ">Rowe 2015b</a>, there were 50 MCI participants and at the end of 18 months of follow‐up, there were seven participants to be evaluated. In <a href="./references#CD012884-bbs2-0006" title="RoweC , DoreV , BourgeatP , ThurfjellL , MacaulayS , WilliamsR , et al. Longitudinal assessment of Abeta accumulation in non‐demented individuals: a 18F‐flutemetamol study. Journal of Nuclear Medicine2015;56:193. ">Rowe 2015c</a>, there were 17 participants with MCI evaluated at 18 months of follow‐up. All of these three studies were focused on change of <sup>18</sup>F‐flutemetamol PET scan retention over time and probably shared participants, so it is possible that these reports referred to the same study. </p> <p>None of the authors answered our email inquiries for additional information.</p> <p><b>Ongoing studies</b> </p> <p>We found two ongoing studies in clinicaltrials.gov. <a href="./references#CD012884-bbs2-0012" title="NCT02164643 . Longitudinal study of brain amyloid imaging in MEMENTO (MEMENTOAmyGing). www.clinicaltrials.gov/show/NCT02164643 (first received16 June 2014). ">NCT02164643</a> is a study that focused on participants with different cognitive spectrums, from isolated cognitive complaints to MCI with a basal <sup>18</sup>F‐flutemetamol or <sup>18</sup>F‐florbetapir PET scan and the progression to a clinical dementia stage according to DSM‐IV and NINCDS‐ADRDA as reference standards for up 24 months follow‐up. This study has been recruiting participants since July 2014 in France. The second study, <a href="./references#CD012884-bbs2-0013" title="NCT02196116 . Amyloïd load in elderly population: effect of cognitive reserve (EDUMA). www.clinicaltrials.gov/show/NCT02196116 (first received 21 July 2014). ">NCT02196116</a>, is focused on the amyloid load in three different participants in a cross‐sectional study: controls, MCI without memory complaints, and MCI with memory complaints. However, they also considered a longer term clinical follow‐up of study participants to investigate the prognosis value of amyloid load for improving the prediction of cognitive decline and disease progression. No further information about the follow‐up was detailed. </p> <p>We found five ongoing studies in the WHO ICTRP register. <a href="./references#CD012884-bbs2-0007" title="EUCTR2011‐001756‐12‐BE . Surrogate markers evaluation in pre‐demented Alzheimer’s disease patients and healthy elderly controls. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001756‐12‐BE (first received 11 April 2012). ">EUCTR2011‐001756‐12‐BE</a> is a study focused on cognitively healthy older people and MCI participants. The main objective is to evaluate, with a multimarker approach, the amnestic MCI participants by quantitative analysis of each biomarker by comparison to a normal database of recruited healthy volunteers and a clinical follow‐up from one to three years with basal <sup>18</sup>F‐flutemetamol. No further details were provided regarding the participants, index test, and reference standard(s). This study has been ongoing since April 2012. The second study, <a href="./references#CD012884-bbs2-0008" title="EUCTR2011‐006195‐39‐SE . An open‐label study to compare the prognostic value of (18F)Flutemetamol PET‐imaging with longitudinal biomarker data in healthy volunteers and patients with mild cognitive impairment. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐006195‐39‐SE (first received 17 January 2012). ">EUCTR2011‐006195‐39‐SE</a>, is focused on MCI participants and the main objective is to examine the efficacy of raised <sup>18</sup>F‐flutemetamol brain uptake for differentiating people with mild cognitive impairment (MCI), who subsequently will develop ADD, from people with MCI who will be cognitively stable or develop other dementias than ADD. No further details were provided regarding the participants, index test, and reference standard(s). This study has been ongoing since January 2012. The third study is <a href="./references#CD012884-bbs2-0011" title="JPRN‐UMIN000019926 . Clinical and neuroimaging study on preclinical Alzheimer's disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000019926 (first received 1 December 2015). ">JPRN‐UMIN000019926</a>, which is focused on preclinical Alzheimer's disease and MCI participants. Their main objective is to discriminate between MCI individuals at risk of development of Alzheimer dementia over an established follow‐up of 36 months. The index test will be 11C‐PiB, <sup>18</sup>F‐florbetapir, or <sup>18</sup>F‐flutemetamol PET scan. No further details were given regarding index test, and reference standard(s). This study has been ongoing since January 2016. The fourth study, <a href="./references#CD012884-bbs2-0010" title="EUCTR2017‐000094‐36‐SE . The BioFINDER 2 study ‐ improved diagnostics and increased understanding of the pathophysiology of cognitive disorders. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017‐000094‐36‐SE (first received 30 January 2017). ">EUCTR2017‐000094‐36‐SE</a>, is focused on MCI, dementia, and healthy elderly people and the main objective is to study the diagnostic accuracy of Tau PET <sup>18</sup>F‐RO6958948 and <sup>18</sup>F‐flutemetamol for identifying healthy elderly individuals and people with subjective or objective mild cognitive symptoms who are at high risk of subsequent development of ADD or other neurodegenerative disorders. The follow‐up was not clearly stated. This study has been ongoing since March 2017. The fifth study, <a href="./references#CD012884-bbs2-0009" title="EUCTR2016‐002635‐15‐NL . Study to Identify Factors associated with Resilience to Clinical Dementia at Old Age ‐ 90+ Study. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2016‐002635‐15‐NL (first received 14 July 2016). ">EUCTR2016‐002635‐15‐NL</a>, is focused on people aged 90 or older. The main objectives are to understand how clinical markers and biomarkers previously identified in younger and older ADD cohorts apply to the extremely old, to identify novel biomarkers linked with resilience to developing ADD in extremely old subjects and the generation of normative data for the oldest, and measure the concordance between amyloid pathology as assessed in CSF and by PET. This study has been ongoing since July 2016. </p> </section> <section id="CD012884-sec-0051"> <h3 class="title">Methodological quality of included studies</h3> <p>We assessed methodological quality using the QUADAS‐2 tool (<a href="./references#CD012884-bbs2-0104" title="WhitingPF , RutjesAWS , WestwoodME , MalletS , DeeksJJ , ReitsmaJB . QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529‐36. ">Whiting 2011</a>). Review authors’ judgements about each methodological quality item for each included study are presented in the Characteristics of included studies table. The overall methodological quality of the studies is summarised in <a href="#CD012884-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD012884-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012884-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_n/nCD012884-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> </div> <p>In the patient selection domain, we considered both studies (<a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a>; <a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a>) to be at unclear risk of bias due to lack of reporting on sampling procedures and exclusion criteria. We stated that the included studies avoided a case‐control design because we only considered data on performance of the index test to discriminate between people with MCI who converted to dementia and those who remained stable. </p> <p>In the index test domain, we considered one study to have a low risk of bias and the other study to be at unclear risk of bias. The Thurfjell study had low risk of bias because the threshold used, according to <a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a> references, was established in the previous study in ADD and HC participants as a SUVR &gt; 1.56 (<a href="./references#CD012884-bbs2-0100" title="VandenbergheR , VanLaereK , IvanoiuA , SalmonE , BastinC , TriauE , et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology2010;68(3):319‐29. ">Vandenberghe 2010</a>), however, the SUVR used in this study was 1.5 and the index test results were interpreted without knowledge of the results of the reference standard. Regarding <a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a>, the interpretation was made without knowledge of the reference standard, however the threshold was not clearly prespecified. In our two additional signalling questions, in the question on whether the index test was interpreted by a trained reader physician, this risk was unclear due to lack of information in the Thurfjell study, but no risk was identified in the <a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a> study. On the other hand, the other signalling question was rated as low risk in the Thurfjell study because there was a clear definition of a positive result, and unclear in <a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a> due to lack of information. </p> <p>In the reference standard domain, we considered the Thurfjell study to have an unclear risk of bias because it was not reported if the clinicians conducting follow‐up were aware of the initial <sup>18</sup>F‐flutemetamol result. We were not able to obtain the information about which reference standard was used, or how and by whom this reference standard was obtained, due to poor reporting (<a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a>). We judged <a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a>, to be at a low risk of bias, because the reference standard used was NINCDS‐ADRDA (<a href="./references#CD012884-bbs2-0069" title="McKhannGM , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>) and the CAC were blinded to the <sup>18</sup>F‐flutemetamol PET scan to established the reference standard. </p> <p>In the flow and timing domain, we judged the Thurfjell study to have a high risk of bias because, in our additional signalling question, there were potential conflicts of interest due to financial support for the study (<a href="./references#CD012884-bbs2-0100" title="VandenbergheR , VanLaereK , IvanoiuA , SalmonE , BastinC , TriauE , et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology2010;68(3):319‐29. ">Vandenberghe 2010</a>) and two authors of <a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a> were employees from the manufacturer of the <sup>18</sup>F‐flutemetamol tracer. We judged the <a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a> study as having a high risk of bias due to possible conflict of interest due to financial support by the <sup>18</sup>F‐flutemetamol producer company. </p> <p>For assessment of applicability, there was no concern that the included patients and setting, or the conduct and interpretation of the index test, did not match the review question; however, the target condition (as defined by the reference standard) was unclear due to lack to information about which reference standard(s) were applied and also the methodology used in the Thurfjell study (<a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a>). On the other hand, in <a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a>, there was concern regarding the index test due to lack to information about the threshold and its definition. </p> </section> <section id="CD012884-sec-0052"> <h3 class="title" id="CD012884-sec-0052">Findings</h3> <p>The results of the included studies are summarised in <a href="./references#CD012884-fig-0004" title="">Data table 1</a>. Additionally, the summary of main results for the included studies are presented in the <a href="./full#CD012884-tbl-0001">summary of findings Table</a>. </p> <p><b><sup>18</sup>F‐flutemetamol for Alzheimer’s disease dementia (ADD)</b> </p> <p><a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a> data on 224 of 232 eligible participants with amnestic MCI (diagnosed with Petersen criteria (not clear which of them were used), using NINCDS‐ADRDA (<a href="./references#CD012884-bbs2-0069" title="McKhannGM , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>)) had a sensitivity of 64% (95% CI 53 to 75) and a specificity of 69% (95% CI 60 to 76) to predict the progression from amnestic MCI to ADD at three years follow‐up. Of 232 participants who were given an initial clinical diagnosis of amnestic MCI, the study had data on 224 of them at the follow‐up; 52 were true positive, 45 were false positive, 29 were false negative, and 98 were true negative (<a href="#CD012884-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD012884-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of 18F‐flutemetamol." data-id="CD012884-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_n/nCD012884-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of <sup>18</sup>F‐flutemetamol. </p> </div> </div> </div> <p>The criteria for <sup>18</sup>F‐flutemetamol PET scan positivity was a visual assessment done by five blinded and trained readers, and they established the positivity or negativity of the PET scan according to the majority readings. </p> <p><a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a> data on 19 of 20 eligible participants with amnestic MCI (diagnosed with Petersen criteria (<a href="./references#CD012884-bbs2-0080" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999;56(3):303‐8. ">Petersen 1999</a>), using a nonspecified reference standard, probably NINCDS‐ADRDA (<a href="./references#CD012884-bbs2-0069" title="McKhannGM , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>) and <a href="./references#CD012884-bbs2-0017" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>) had a sensitivity of 89% (95% CI 52 to 100) and a specificity of 80% (95% CI 44 to 97) to predict the progression from amnestic MCI to ADD at two years follow‐up. Of 20 participants who were given an initial clinical diagnosis of amnestic MCI, the study had data on 19 of them at the follow‐up; 8 were true positive, 2 were false positive, 1 was false negative and 8 were true negative (<a href="#CD012884-fig-0003">Figure 3</a>). </p> <p>The criterion for <sup>18</sup>F‐flutemetamol PET scan positivity was a quantitative threshold with a SUVR &gt; 1.5 and the measures of <sup>18</sup>F‐flutemetamol amyloid retention were:; lateral frontal cortex (FRO), lateral temporal cortex (LTC), lateral parietal cortex (PAR), anterior cingulate (ANC), occipital cortex (OCC), and pons (PON); a cerebellar ROI served as the reference region. </p> <p>No data were available regarding the other two target conditions in this Cochrane review: progression from MCI to another form of dementia (non‐ADD) or progression from MCI to any form of dementia. </p> <p><b>Investigation of heterogeneity</b> </p> <p>The planned investigations were not possible due to the limited number of studies available for the analysis. </p> <p><b>Sensitivity analyses</b> </p> <p>There were insufficient studies identified to permit any sensitivity analyses.</p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012884-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012884-sec-0053"></div> <section id="CD012884-sec-0054"> <h3 class="title" id="CD012884-sec-0054">Summary of main results</h3> <p>The volume and quality of evidence regarding the DTA of <sup>18</sup>F‐flutemetamol for early diagnosis of ADD and other dementias in people with MCI is limited. We identified two studies in this SR. However, we were not able to construct a meta‐analysis. We did not perform sensitivity analyses and were not able to analyse the heterogeneity. </p> <p>The two included studies addressed the DTA of <sup>18</sup>F‐flutemetamol analysed quantitatively with a threshold of SUVR &gt; 1.5 (<a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a>) or by visual assessment (<a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a>) for the prediction of progression from MCI to ADD at follow‐up. The results are summarised in the 'Summary of findings' table (<a href="./full#CD012884-tbl-0001">summary of findings Table</a>). The studies were evaluated as at high risk of bias mainly due to the potential conflict of interest because of the financial support of the company that manufactured the <sup>18</sup>F‐flutemetamol tracer. The study had no information about the progression to any form of dementia or any other form of dementia (non‐ADD). Regarding our objectives, to determine the DTA of the <sup>18</sup>F‐flutemetamol PET scan for detecting participants with MCI at the time of performing the test who would clinically progress to ADD, or to other forms of dementia or any form of dementia at follow‐up, the results were the following: </p> <p><b><sup>18</sup>F‐flutemetamol PET scan for Alzheimer’s disease dementia (ADD)</b> </p> <p>Progression from MCI to ADD at three years of follow‐up by visual assessment had a sensitivity of 64% (95% CI 53 to 75) and a specificity of 69% (95% CI 60 to 76) respectively (n = 224) (<a href="#CD012884-fig-0003">Figure 3</a>). </p> <p>Progression from MCI to ADD at two years of follow‐up by quantitative assessment by SUVR had a sensitivity of 89% (95% CI 52 to 100) and a specificity of 80% (95% CI 44 to 97) respectively (n = 19) (<a href="#CD012884-fig-0003">Figure 3</a>). </p> <p>The DTA of<sup>18</sup>F‐flutemetamol includes a wide range of low‐to‐moderate and good sensitivity and specificity for predicting progression to ADD through visual or SUVR assessment evaluation at different follow‐up. In other words, the low‐to‐moderate or good sensitivity could be affected by a relatively high false negative rate, admittedly from only one study. As with other amyloid tracers, <sup>18</sup>F‐flutemetamol probes the detection of amyloid plaques that are composed of insoluble Aβ peptides (<a href="./references#CD012884-bbs2-0036" title="European Medicines Agency. Vizamyl. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002557/WC500172950.pdf (accessed 8 April 2015). ">EMA 2014</a>; <a href="./references#CD012884-bbs2-0039" title="Food , DrugAdministration . Vizamyl. www.accessdata.fda.gov/drugsatfda_docs/label/2014/203137s002lbl.pdf (accessed 8 April 2015). ">FDA 2014</a>). However, the soluble Aβ oligomers play a central role in Alzheimer's pathogenesis in the amyloid hypothesis (<a href="./references#CD012884-bbs2-0050" title="HaydenEY , TeplowDB . Amyloid β‐protein oligomers and Alzheimer’s disease. Alzheimer's research &amp; therapy2013;5(6):1‐11. ">Heyden 2013</a>), with the possibility of producing false negatives. In addition, amyloid tracers are not be able to bind to the other histopathologic core of Alzheimer's disease ‐ the neurofibrillary tangles (NFTs). There is evidence that suggests that plaques and tangles independently contribute to cognitive impairment over the clinical course of Alzheimer's disease (<a href="./references#CD012884-bbs2-0096" title="Serrano‐PozoA , QianJ , MonsellSE , FroschMP , BetenskyRA , HymanBT . Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. Journal of Neuropathology and Experimental Neurology2013;72(12):1182‐92. ">Serrano‐Pozo 2013</a>). Moreover, in another cohort study, the NFT formation might be either unrelated to amyloid plaques formation or a temporally distinct process, or both<b>(</b><a href="./references#CD012884-bbs2-0090" title="RoyallDR , PalmerRF . The temporospatial evolution of neuritic plaque‐related and independent tauopathies: implications for dementia staging. Journal of Alzheimer’s Disease2014;40(3):541‐9. ">Royall 2014</a><b>)</b>. Another reason that could explain false negative results is that those with probable ADD may have multiple brain pathologies, most commonly Alzheimer's disease with macroscopic infarcts, followed by Alzheimer's disease with neocortical Lewy body disease, and, like ADD, MCI pathology could be heterogeneous (<a href="./references#CD012884-bbs2-0092" title="SchneiderJA , ArvanitakisZ , BangW , BennettDA . Mixed brain pathologies account for most dementia cases in community‐dwelling older persons. Neurology2007;69(24):2197‐204. ">Schneider 2007</a>; <a href="./references#CD012884-bbs2-0093" title="SchneiderJA , ArvanitakisZ , LeurgansSE , BennettDA . The neuropathology of probable Alzheimer disease and mild cognitive impairment. Annals of neurology2009;66(2):200‐8. ">Schneider 2009</a>). </p> <p>In addition, the low‐to‐moderate or good specificity could be affected by a high false positive rate. A positive <sup>18</sup>F‐flutemetamol PET scan for Aβ, has been found in other neurological conditions. It was positive in pure vascular dementia and Lewy body dementia cases confirmed by autopsy (<a href="./references#CD012884-bbs2-0099" title="ThalDR , BeachTG , ZanetteM , HeurlingK , ChakrabartyA , IsmailA , et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid‐β pathology. Alzheimer's &amp; Dementia2015;11(8):975‐85. ">Thal 2015</a>). On the other hand, in other amyloid biomarkers like PET PiB, and closer to the <sup>18</sup>F‐flutemetamol chemical composition, the false positive rate could be explained because it has affinity to amyloid in vessel walls, in particular to cerebral amyloid angiopathy (CAA) (<a href="./references#CD012884-bbs2-0108" title="ZhangS , SmailagicN , HydeC , Noel‐StorrAH , TakwoingiY , McShaneR , et al. 11C‐PIB‐PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD010386.pub2] ">Zhang 2014</a>). We would think that the pathological diagnosis of some people with clinical probable ADD may be vascular dementia secondary to CAA and some MCI participants may have vascular MCI due to CAA. The other important option for a high false positive rate is that in many people without cognitive impairment it is possible to find Aβ deposits at their autopsies (<a href="./references#CD012884-bbs2-0042" title="GelberRP , LaunerLJ , WhiteLR . The Honolulu‐Asia Aging Study: epidemiologic and neuropathologic research on cognitive impairment. Current Alzheimer research2012;9(6):664‐72. ">Gelber 2012</a>), generating some doubts about the real pathophysiological relevance of the Aβ hypothesis in Alzheimer's disease. </p> <p>Another important factor to be considered in predicting the progression to ADD and the number of false positives is the duration of follow‐up, because the reported progression rate of MCI to ADD is between 8% and 16% per year (<a href="./references#CD012884-bbs2-0071" title="MitchellAJ , Shiri‐FeshkiM . Rate of progression of mild cognitive impairment to dementia‐‐meta‐analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica2009;119(4):252‐65. ">Mitchell 2009</a>). Therefore, a high percentage of people with MCI at the time of performing the test would progress to Alzheimer’s disease if we had included a longer follow‐up period, and this would affect the predictive DTA of the <sup>18</sup>F‐flutemetamol PET scan. However, the progression rate at two years was 47.4% and 36.2% at three years of follow‐up in the included studies. The latest was found in a systematic review with PiB PET where the data were separated into short follow‐up and longer than two years of follow‐up. They included five studies with 102 participants in total, with a specificity between 58% to 100% (<a href="./references#CD012884-bbs2-0062" title="MaY , ZhangS , LiJ , ZhengDM , GuoY , FengJ , et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow‐up: a meta‐analysis. Medicine2014;93(27):1‐12. ">Ma 2014</a>). However, in our study, the follow‐up time and percentage of progression were discordant; the progression rate at two years was 47.4% and 36.2% at three years of follow‐up in the included studies. This difference is probably explained by the setting of recruitment or demographic or MCI characteristics and possibly other underlying factors that were affecting the data (<a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a>; <a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a>). As a consequence, due to the lack of data, we were not able to investigate the effect of the follow‐up on the progression rate from MCI to ADD or any form of dementia. </p> <p>On the other hand, MCI subtypes have been related to progression to dementia. A large longitudinal study with 550 MCI participants indicated that the MCI subtype, presence of storage memory impairment, multiple domain condition, and presence of APOE ϵ4 allele increased the risk of progression to dementia. Multivariate survival and Kaplan‐Meier analyses showed that amnestic MCI with storage memory impairment had the most and closest risk of progression to dementia (<a href="./references#CD012884-bbs2-0037" title="EspinosaA , AlegretM , ValeroS , Vinyes‐JunqueG , HernandezI , MauleonA , et al. A longitudinal follow‐up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. Journal of Alzheimer’s Disease2013;34(3):769‐80. ">Espinosa 2013</a>). In our review, both studies included only amnestic participants, therefore, we could predict a worse accuracy if non‐amnestic MCI were included. Additionally, some other risk factors like family history of dementia, APOE ϵ4 allele presence, and Aβ and tau protein levels in cerebrospinal fluid may contribute to a faster progression rate to dementia. In conclusion, further reviews that include high quality research with more detailed data about the characteristics of MCI are required to not only explore the underlying mechanisms but also to elucidate the causal pathways that link <sup>18</sup>F‐flutemetamol PET scan positivity of diverse MCI subtypes and disease progression. </p> </section> <section id="CD012884-sec-0055"> <h3 class="title" id="CD012884-sec-0055">Strengths and weaknesses of the review</h3> <p>We conducted an extensive, comprehensive, and sensitive literature search, using eleven different electronic databases without any limit to language or date. However, we were only able to include two studies with 243 participants, therefore, our DTA estimates are relatively imprecise. This paucity of evidence reflects the very significant challenges inherent in conducting long term prospective studies of well‐characterised participants, followed up to the point of progression to clinical dementia. The methodological quality assessment and data syntheses were based on the recommended methods (<a href="./references#CD012884-bbs2-0029" title="DavisDHJ , CreavinST , Noel‐StorrA , QuinnTJ , SmailagicN , HydeC , et al. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010460] ">Davis 2013</a>). To increase the reliability of our findings, we included only studies that fulfilled delayed verification of progression from MCI to ADD or other form of dementia (non‐ADD) or any form of dementia at follow up. </p> <p>The included studies had significant methodological limitations that weakened confidence in the results of this SR. First, considerable uncertainty remains concerning the clinical diagnosis of ADD; the anatomopathological diagnosis would be the better way to probe the diagnosis, but there was not a clear definition of a positive index test in one study, the reference standard in one study was not explicitly described, and the major problem was the potential conflict of interest with the company that produced the tracer in both studies. </p> <p>The selection of participants with MCI in these studies could be another weakness, because we did not have all the necessary baseline data in the ClinicalTrials.gov registered study included in this SR (<a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a>), and what would happen in those with non‐amnestic MCI in the future. However, this selection of participants, such as type of MCI, age, presence of the APOE ϵ4 allele, structural abnormality at MRI, hypometabolism at FDG‐PET scan, and alteration in cerebrospinal fluid could help determine different subgroups of people at higher risk of developing dementia at follow‐up, and perform a stratification that could help avoid biases, and develop more efficient studies in the future (<a href="./references#CD012884-bbs2-0024" title="CaroliA , PrestiaA , WadeS , ChenK , AyutyanontN , LandauSM , et al. Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. Alzheimer disease and associated disorders2015;29(2):101‐9. ">Caroli 2015</a>; <a href="./references#CD012884-bbs2-0045" title="HampelH , ListaS , KhachaturianZ . Development of biomarkers to chart all Alzheimer’s disease stages: The royal road to cutting the therapeutic Gordian Knot. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association2012;8(4):312‐36. ">Hampel 2012</a>; <a href="./references#CD012884-bbs2-0107" title="WolzR , SchwarzAJ , GrayKR , YuP , HillDL , Alzheimer's Disease Neuroimaging Initiative. Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. Neurology2016;87(12):1235‐41. ">Wolz 2016</a>). <a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a> had some information about age, presence of the APOE ϵ4 allele, and amnestic MCI stage (early/late) in a Cox regression, but without useable data for this DTA review. The Thurfjell study tried to correlate SUVR and hippocampus volume (<a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a>). </p> <p>Finally, an important weakness of this SR was the nonresponse of the authors about their studies. This has resulted in a lack of data for analysis in this review. </p> </section> <section id="CD012884-sec-0056"> <h3 class="title" id="CD012884-sec-0056">Applicability of findings to the review question</h3> <p>Regarding the question of this review: Could the <sup>18</sup>F‐flutemetamol PET scan identify those MCI participants who would progress to clinical dementia at follow up?. There were applicability concerns in the index test in one study that did not provide a clear definition of what was considered a <sup>18</sup>F‐flutemetamol positive result. There were also applicability concerns in the reference standard in one study, mainly due to lack of information regarding how the clinical progression to ADD was made. However, due to the limited number of included studies and levels of heterogeneity with respect to the two domains mentioned above, it was difficult to determine to what extent the findings from this review could be applied to clinical practice. </p> <p>The DTA of the <sup>18</sup>F‐flutemetamol PET scan for identifying Alzheimer’s disease pathology and identifying those people with MCI who would convert to ADD could be affected by a number of factors that have not been determined so far. First, and most important, is the lack of a large study to evaluate this question. We included only two studies that addressed the question with 243 participants at follow‐up. Second, the quantitative criterion used for several studies is not the actually approved criterion of FDA and EMA, because they approved the visual assessment interpretation. However, in this SR we included one study with quantitative evaluation and the other with visual assessment, with lack of information regarding how that visual assessment was made. </p> <p>We await new studies using the FDA and EMA approval visual assessment criteria in longitudinal studies. The <sup>18</sup>F‐flutemetamol test is expensive, therefore, we believe it is important to clearly determine its DTA prior to recommending its adoption in clinical practice. The actual sensitivity and specificity are too low to have enough accuracy to be used in clinical practice to predict the progression from MCI to ADD. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012884-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/urn:x-wiley:14651858:media:CD012884:CD012884-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_t/tCD012884-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD012884-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_n/nCD012884-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_n/nCD012884-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012884-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/urn:x-wiley:14651858:media:CD012884:CD012884-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_t/tCD012884-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012884-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_n/nCD012884-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_n/nCD012884-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012884-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/urn:x-wiley:14651858:media:CD012884:CD012884-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_t/tCD012884-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of 18F‐flutemetamol." data-id="CD012884-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_n/nCD012884-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of <sup>18</sup>F‐flutemetamol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_n/nCD012884-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012884-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/urn:x-wiley:14651858:media:CD012884:CD012884-TST-001" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_t/tCD012884-TST-001.xxx" target="_blank"><b></b></a></p> </div><img alt="18F‐flutemetamol." data-id="CD012884-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_n/nCD012884-TST-001.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 1</div> <div class="figure-caption"> <p>18F‐flutemetamol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012884/references#CD012884-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012884/media/CDSR/CD012884/image_n/nCD012884-TST-001.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012884-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">DTA of 18F‐flutemetamol to predict the progression to ADD in people with MCI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>What is the diagnostic accuracy of <sup>18</sup>F‐flutemetamol PET amyloid biomarker for predict progression to ADD in people with MCI? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>Descriptive</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Patient population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Participants diagnosed with MCI at the time of performing the test using any of the Petersen criteria or Winblad criteria or CDR = 0.5 or any of the 16 definitions included by Matthews (<a href="./references#CD012884-bbs2-0064" title="MatthewsFE , StephanBC , McKeithIG , BondJ , BrayneC , Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008;56(8):1424‐33. ">Matthews 2008</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Sources of referral</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Not reported (n = 2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>MCI criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Petersen criteria (n = 2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Sampling procedure</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Unclear (n = 2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Prior testing</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>The only testing prior to performing the <sup>18</sup>F‐flutemetamol PET amyloid biomarker was the application of diagnostic criteria for identifying participants with MCI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Settings</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Secondary care (n = 1)</p> <p>Not reported (n = 1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Index test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><sup>18</sup>F‐flutemetamol PET </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Threshold pre‐specified at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Yes (n=1)</p> <p>Unclear (n=1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Threshold interpretation</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Visual (n = 1)</p> <p>Quantitative (n = 1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Thershold</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>SUVR (Standardised Uptake Volume ratio) of ROI: &gt; 1.5 (n = 1)</p> <p>Not specified: analytical visual approach of ROI: (n = 1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><sup>18</sup>F‐flutemetamol retention region </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Global cortex (n = 1)</p> <p>Not reported (n = 1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Reference Standard</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>For Alzheimer’s disease dementia:</p> <p>NINCDS‐ADRDA (n = 1)</p> <p>Unclear (n = 1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Target condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Progression from MCI to Alzheimer’s disease dementia or any other forms of dementia (non‐ADD) or any form of dementia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Included studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Prospectively well‐defined cohorts with any accepted definition of MCI (as above). Two studies (N = 252 participants) were included. Number of participants included in analysis: 243 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Quality concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><a href="./references#CD012884-bbs2-0001" title="EUCTR2009‐010227‐62‐GB . A principal open‐label study to assess the prognostic usefulness of flutemetamol (F18) injection for identifying subjects with amnestic mild cognitive impairment who will convert to probable Alzheimer’s disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐010227‐62‐GB (first received 6 July 2009). NCT01028053 . Assess the prognostic usefulness of flutemetamol (18F) injection for identifying subjects with amnestic mild cognitive impairment who will convert to clinically probable Alzheimer's disease. www.clinicaltrials.gov/show/NCT01028053 (first received 9 December 2009). ">NCT01028053</a>: </p> <p>Patient selection and index test QUADAS‐2 domain: unclear risk of bias</p> <p>Reference standard domain: low risk of bias</p> <p>Flow and timing domain: high risk of bias</p> <p>There were unclear concerns about applicability in the patient selection and index test domain.<br/> <a href="./references#CD012884-bbs2-0002" title="ThurfjellL , LötjönenJ , LundqvistR , KoikkalainenJ , SoininenH , WaldemarG , et al. Combination of biomarkers: PET [18F] flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neuro‐degenerative Diseases2012;10:246‐9. ">Thurfjell 2012</a>: </p> <p>Patient selection and index test QUADAS‐2 domain: low risk of bias</p> <p>Reference standard domain: unclear risk of bias</p> <p>Flow and timing domain: high risk of bias.</p> <p>There was unclear concern about applicability in the reference standard domain.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Limitations</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Limited investigation of heterogeneity and sensitivity analysis due to an insufficient number of studies. </p> <p>We were unable to evaluate progression from MCI to any other form of dementia (non‐ADD) or any form of dementia due to lack of included studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Cases/Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Sensitivity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Specificity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Consequences in a cohort of 100</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion converting<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missed cases<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overdiagnosed</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Alzheimer's disease dementia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐flutemetamol with visual assessment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81/224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64% (95% CI 53% to 75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69% (95% CI 60% to 76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐flutemetamol with SUVR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89% (95% CI 52% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80% (95% CI 44% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Investigation of heterogeneity and sensitivity analysis</b>: The planned investigations were not possible due to the limited number of studies available for each analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Conclusions:</b><sup>18</sup>F‐flutemetamol PET scan is not an accurate test for detecting progression from MCI to Alzheimer’s disease dementia. The strength of the evidence was weak because of considerable variation in study methods, unclear methodological quality due to poor reporting, and high risk of bias due to possible conflict of interest. There is a need for conducting studies using standardised <sup>18</sup>F‐flutemetamol PET scan methodology in larger populations. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1. Proportion converting to ADD in each included study</sup> </p> <p><sup>2. Missed and overdiagnosed numbers were computed using the proportion converting to the target condition.</sup> </p> <p><sup>ADD: Alzheimer's disease dementia<br/> CDR: Clinical Dementia Rating<br/> MCI: Mild cognitive impairment<br/> NINCDS‐ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association<br/> PET: Positron emission tomography</sup> </p> <p><sup>QUADAS‐2: Quality Assessment of Diagnostic Accuracy Studies‐2<br/> ROI: Region of interest<br/> SUVR: Standardised uptake value ratio</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">DTA of 18F‐flutemetamol to predict the progression to ADD in people with MCI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012884/full#CD012884-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012884-tbl-0002"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p>Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">1 18F‐flutemetamol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012884/references#CD012884-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012884&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012884-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012884-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012884-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD012884-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012884-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012884-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012884\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012884\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012884\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012884"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012884\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012884\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012884\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012884\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012884\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012884"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012884\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012884\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012884\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012884"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012884\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012884\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012884\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012884"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012884&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012884';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012884/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012884/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012884%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724928318"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012884/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724928322"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012884/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6ec28a7ff4ca',t:'MTc0MDcyNDkyOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 